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Morphological Adaptive Radiotherapy in Head and Neck
Cancer – assessing the impact of weekly anatomical changes
in Intensity Modulated Radiation Therapy
Farhannah Aly
A thesis for Master of Philosophy
Centre for Medical Radiation Physics
University of Wollongong

Abstract
The treatment of mucosal Head and Neck (H+N) cancers with radiotherapy has seen considerable
technological development over recent years; from large non-conformal fields, to threeDimensional Conformal Radiation Therapy (3-D CRT) and subsequently the introduction of
Intensity Modulated Radiation Therapy (IMRT), Volumetric Modulated Arc Therapy (VMAT) and
other radiation therapy delivery techniques, such as proton therapy. When compared to older
“conventional” techniques, the IMRT planning process results in improved dose to tumour volumes,
whilst simultaneously reducing Organ at Risk (OAR) dose; i.e. an improvement of the therapeutic
index. This dosimetric improvement translates into clinical benefits; especially in terms of reduced
radiotherapy toxicity and Quality of Life.
Whilst IMRT may deliver highly conformal, high dose Radiation Therapy (RT); morphological
variations in normal tissue and tumour anatomy occur during the course of RT. These variations
can result in inadequate dose delivery, requiring reoptimisation of the IMRT plan. Adaptive
Radiation Therapy (ART) is an approach whereby the treatment plan is modified to account for

xv

these changes in patient anatomy. There is no consensus as to the optimal timing, method or
frequency of an ART approach; as well as identifying the patients who may derive the most benefit.
This thesis describes a prospective investigation of weekly Computed Tomography (CT) scanning
and plan adaptation if tumour or OAR coverage was unacceptable. The anatomical changes
occurring in tumour and normal tissues during radiotherapy, and the subsequent effect on dose
delivery, are quantified. The impact of plan adaptation on subsequent dose delivery is examined.
Tumour volumes reduced in volume over the treatment period. At the end of treatment, the nodal
volume demonstrated greater volume reduction (44 %) compared to the primary tumour volume
(25 %), and the parotid and submandibular glands showed a volume reduction of 28 % and 26 %
respectively. Whilst the whole parotid gland did not demonstrate a significant displacement; a
medial shift of the lateral portion of the gland was demonstrated. A superior displacement of the
submandibular glands was also observed.
Inadequate Planning Target Volume (PTV) coverage was demonstrated in 80 % of the patient
cohort, requiring one or more adaptations of the IMRT plan during the course of treatment. In all
cases, IMRT plan adaptation was required due to inadequate PTV coverage, rather than excessive
OAR dose with 41 % of replanning events occurring at or before fraction 10; demonstrating that
inadequate IMRT plan dosimetry can occur early in the treatment course. Adaptation of the IMRT
plan led to a significant improvement in PTV coverage, as well as reduced dose to the parotid glands
and spinal cord.
Due to the small cohort of patients, this investigation is regarded as an exploratory study. However,
the findings add to the literature supporting the use of an ART protocol for Head and Neck Cancer
(HNC) patients. Implementation of a clinical ART protocol should include imaging, contouring
volumes on new anatomy and dose calculation within the first 10 fractions. Further imaging and
assessment of dose delivery should be undertaken at multiple time points during the course of
Radiation Therapy (RT); as often as departmental resources allow.
Significant resources are required to implement an ART strategy for all HNC patients. Identifying
those patients who would most benefit from ART remains challenging. No recommendation can be
made for selecting patients at highest risk for inadequate dose delivery; however patients with a
large initial volume of nodal disease should be considered for more frequent imaging and plan
assessment. Streamlining the ART process may also result in a more practical ART strategy; for

xvi

example the utilization of dose calculation on Cone Beam CT Imaging, and in particular automated
contour propagation.
Whilst a benefit of ART in terms of dose distribution has been demonstrated in this investigation;
larger prospective studies are required to establish whether a dosimetric benefit translates into an
advantage in terms of clinical outcome. Ultimately, an ART strategy would only be worthwhile if it
results in an improvement in patient clinical outcomes.

xvii

xviii

Chapter 1
Introduction
1.1 Introduction
Head and neck cancer (HNC) is the eighth most commonly diagnosed cancer in Australia, with an
estimated age-standardised incidence rate of 17 cases per 100,000 population. Of the 4409 new
cases of HNC diagnosed in 2013, 72 % of them occurred in males. The age-standardised mortality
from HNC in Australia in 2014 was 3.8 per 100,000 population; translating to 1040 deaths in that
year (1).
The treatment of mucosal HNC with radiotherapy has seen considerable technological development
over recent years; from large non-conformal fields, to 3-D CRT and subsequently the introduction of
IMRT, VMAT and other radiation therapy delivery techniques, such as proton therapy. This has
been possible due to the introduction of CT imaging in the treatment planning process, combined
with inverse planning and beam modulation; allowing for tighter sculpting of dose around the
target volume and improved avoidance of certain organs at risk (2). This dose sculpting leads to
steep dose gradients in anatomical regions where the tumour target volume (TV) and OARs are in
close proximity. Due to the presence of these steep dose gradients, set-up error and anatomical
changes during the course of radiation therapy may result in larger dose inaccuracy within tumour
volumes and organs at risk. Image Guided Radiation Therapy (IGRT) however, improves the
precision of radiation dose delivery (3), and daily image guidance with either kilovoltage or
megavoltage imaging is employed with all modern radiation delivery techniques to reduce the
impact of interfractional variation.
When compared to older “conventional” techniques, the IMRT planning process results in improved
dose to tumour volumes, whilst simultaneously reducing OAR dose (3,4); i.e. an improvement of the
therapeutic index. This dosimetric improvement has resulted in clinical benefits; especially in terms
1

of reduced radiotherapy toxicity (4,5). Prospective randomised controlled studies (6,7) and case
series (4,8) have demonstrated reduced parotid gland toxicity using an IMRT technique, in terms of
xerostomia incidence, salivary function recovery and Quality of Life, compared to conventional
radiotherapy. Similarly, case series report an improved overall survival and disease free survival
(though no locoregional control improvement) when comparing IMRT with the 3D-CRT technique
in various head and neck tumour sites (4,9).
Patients undergoing radiotherapy for HNC experience morphological changes during the course of
treatment due to weight loss, tumour mass change, variations in organs at risk (e.g. parotid glands),
reduction in muscle and fat volume and tissue oedema (3,10–14). Figure 1.1 demonstrates the
external contour change seen in one patient 20 fractions into a 35 fraction treatment. Figure 1.2
shows PTV contour volume reduction by fraction 20, predominantly due to shrinkage of large
lymph nodes in the right side of the neck. On clinical examination, the tumour mass had reduced in
size and the patient had also lost weight. The resulting external contour reduction led to the
thermoplastic immobilisation mask becoming too loose, as well as inadequate dose delivery,
requiring adaptation of the IMRT plan.

2

a

b

Figure 1.1. Transverse CT slice demonstrating the external contour shrinkage after 20 fractions of
IMRT in a patient being treated for H+N cancer. This patient had large pathological lymph nodes in
the right side of the neck, which rapidly reduced in size within the first 20 fractions of treatment;
resulting in a immobilisation mask that became too loose for treatment. (a)- bolus at planning
stage; (b)- bolus at fraction 20. Red double-headed arrow- demonstrates the shrinkage of external
contour at fraction 20.
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Figure 1.2. Transverse, coronal and sagittal slices of patient (whose external contour is shown in
figure 1.1), demonstrating reduction in PTV volume at fraction 20. Green- PTV at fraction 0; RedPTV at fraction 20; Light blue- spinal canal. The PTV lines have not been adjusted to within skin
surface in this example, but are adjusted for IMRT planning purposes.

4

Whilst IMRT may deliver highly conformal, high dose RT; morphological variations in normal tissue
and tumour anatomy which occur during the course of RT, are not specifically accounted for when
generating the IMRT plan, since the planned dose distributions are obtained from a single planning
CT dataset obtained approximately one to two weeks prior to the start of treatment. In addition,
during the IMRT planning process, the deliberate placement of areas of steep dose gradient in
patient tissue where Planning Target Volumes and Organs at Risk are in close proximity, results in a
dose distribution which is sensitive to small changes in patient anatomy (15). Adaptive Radiation
Therapy is an approach whereby the treatment plan may be modified during a course of RT to
account for such changes in patient anatomy. If ART is employed when the patient thermoplastic
immobilisation mask is noted to be loose or when clinical examination finds that enlarged tumour
volumes have shrunk, there is a risk that ART occurs later than when it may have been initially
required. More subtle anatomical changes, resulting in inadequate dose deposition, may occur
earlier and may not be detected by clinical evaluation alone, an example of which is shown in Figure
1.3.
This thesis is an investigation of the anatomical changes occurring in tumour and normal tissues
during radiotherapy; and the subsequent effect on dose delivery. The impact of introducing an ART
protocol on dose delivery is also reported.

5

Figure 1.3. a) Transverse, b) sagittal and c) coronal views of a patient CT scan at planning and midtreatment, demonstrating subtle changes in external contour (circled) which would be undetectable
on clinical assessment.
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1.2 Project Aims
With the widespread introduction of IMRT in the treatment of HNC, the clinical focus has been on
improving the therapeutic window by better delineation of structures and reduction of movement
uncertainties. Questions relating to changes in structures over the course of therapy have not been
addressed until more recently in the radiation oncology and medical physics literature.
Aim 1. Investigate and quantify the anatomical changes occurring in patients during HNC
radiotherapy.
Research questions:
a. What volumetric changes are observed in the Target Volumes during HNC IMRT?
b. What volumetric and geometric changes are observed in the parotid and submandibular
glands during HNC IMRT?
c. Are any changes in subcutaneous fat volume detectable during HNC IMRT?
Aim 2. To investigate the impact of anatomical changes on dose delivery to the Target Volume,
parotid glands (PG) and spinal canal; and the impact of IMRT plan adaptation on subsequent dose
delivery to these structures.
Research questions:
a. What doses are delivered to the PTVs, PGs and spinal canal during unadapted HNC
IMRT?
b. What is the impact of plan adaptation on the PTV dose, PG dose and spinal canal dose?
c. Do any factors correlate as predictors of when the IMRT plan requires an adaptation?
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1.3 Chapter Overview
Literature relevant to this investigation is explored in Chapter 2. The methodology, details of
statistical analysis and details of the ART protocol employed are presented in Chapter 3.
Chapters 4 to 6 focus on presenting the results. General results, regarding the frequency and timing
of plan adaptations, as well as changes in patient weight and nutritional status are conveyed in
Chapter 4. The exploration of weight and nutritional score, as correlates for unacceptable dose
delivery are also discussed in Chapter 4. Chapter 5 describes the volumetric changes occurring in
the various Target Volumes during H+N IMRT. The PTV, Clinical Target Volume (CTV) and Gross
Tumour Volume (GTV) volume changes are quantified and significant trends described. The
volumetric and geometric changes occurring in the parotid and submandibular glands are
presented. This chapter also describes the change in fat volume within the head and neck region,
looking at the volume differences across a range of CT slices. Chapter 6 describes the dosimetric
changes occurring in both unadapted and adapted treatment plans, as quantified on the weekly CT
imaging.
Chapter 7 summarises the research findings, with a discussion on issues arising from this
investigation. Recommendations derived from this investigation are also presented in this chapter.
Suggestions for future research are explored at the end of chapter 7.
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Chapter 2
Literature Review
2.1 Changes in Patient Weight Occurring during Radiotherapy
for Head and Neck Cancer
Patients can experience weight loss during their cancer journey, due to a multitude of reasons
(16,17), including:
i.

Reduction in appetite; which can occur as a result of treatment side effects, but also due to
anxiety, stress and fatigue.

ii.

Reduction in nutritional intake due to tumour effects; including pain, difficulty chewing or
swallowing and cancer cachexia.

iii.

Reduction in nutritional intake due to treatment side effects; including mucositis, nausea,
difficulty with swallowing, pain, taste and smell aversion.

iv.

Fatigue; which impacts the ability to purchase and prepare food.

The average reported weight loss in patients, undergoing radiation therapy for HNC, ranges
between 6 to 11 % (10,18–30).

2.2 Anatomical Changes in Tumour Volumes Occurring during
Radiotherapy for Head and Neck Cancer
Tumour volumes have been shown to reduce in size during the course of radiation therapy.
Quantifying the extent of TV reduction is challenging from existing literature, as investigators
report volume changes in different target volumes; with volume changes described in the GTV
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(nodal or primary or combined) (10,12,18–20,25,27,29,31–37), CTV (high or low
dose)(11,12,23,27,29,36–41) or PTV (high or low dose) (20,27,29,36,42). In addition, the time
points at which volume changes are reported also vary significantly; at any point from the first half
of RT treatment and until the end of RT.
It should also be kept in mind that volume change of the primary tumour GTV may be difficult to
measure accurately using CT imaging, as the border of the primary tumour GTV may be difficult to
determine on subsequent CT scans (and especially in the absence of intravenous contrast use).
Castadot et al (12), performed CT scans with intravenous (i.v.) contrast as well as Positron
Emission Tomography (PET) scans to investigate changes in tumour volumes and organs at risk
during the course of RT. The use of i.v. contrast allowed for the delineation of tumour volumes with
greater accuracy. The GTV volumes were delineated manually at each per-treatment scan; whilst
the CTV volumes were generated using deformable image registration, with autosegmentation and
manual correction if required. They report, at the end of treatment, a significant daily reduction of
3.2 % for the GTV primary tumour volume, 2.2 % for the GTV nodal volume and 2.4 % for the high
dose CTV volume. The low dose CTV volume demonstrated a non-significant daily volume reduction
of 0.7 %.
In two studies investigating changes in primary tumour GTV volumes and surrounding tissues
using MRI scanning, the authors report a reduction in primary tumour GTV of 70 % and 84 % at the
end of treatment (37,43). This is similar to reports from numerous CT studies, where GTV reduction
in volume has ranged between 66 % and 80 % at the end of treatment (10,25,32). However, one
study reports a much smaller GTV volume reduction of 17% at the end of treatment (18).
The initial tumour volume may also affect the extent of volume reduction during treatment. Barker
et al (10) report that larger initial GTVs demonstrate a faster rate of volume loss than smaller GTVs;
whilst Wang et al (24) demonstrated that the absolute volume reduction is greater for larger lymph
nodes.
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2.3 Anatomical Changes in Organs At Risk Occurring during
Radiotherapy for Head and Neck Cancer
2.3.1 Parotid Gland
During H+N RT, one or both of the parotid glands are generally adjacent to the high dose PTV.
Portions of the parotid gland may even fall within the high dose PTV, as the PTV is a geometric
construct created by adding an expansion margin to CTV volumes (which may abut the parotid
gland). During IMRT treatment planning, dose to one or both parotid glands is a highly weighted
dose objective. This is because irradiation of the parotid glands leads to short and long-term
toxicity in the form of xerostomia; which can lead to other health impacts (discussed in further
detail in section 2.6).
Therefore the anatomical changes occurring to the parotid gland during treatment for HNC have
been frequently reported. The parotid glands experience a reduction in volume. When measured at
the end of treatment, investigators report an average total volume reduction of between 21 to 59 %
(10,18,21–23,25,30,32,37,38,41,44–46). Some of these studies utilised Cone Beam CT (CBCT)
imaging for their analysis (21,39,44,46,47), others imaged with planning CT scans. The review
article by Brouwer et al (48), pooling data from multiple studies, reports an average volume
reduction of 26  11 % in the parotid glands by the end of radiation therapy. Other investigators
have reported daily volume reductions of 0.6 to 1.5 % (10,12,47,49) or weekly reductions of 1.7 to
7.9 % (25,32,37,38,50).
The parotid glands appear to experience greater volume loss in the first half of the 35 fraction
treatment period; Wang et al (45) report a 20 % volume loss in the first half of treatment and a 11
% volume loss in the second half of treatment; Ahn et al (18) report that the rate of volume loss
stabilized by fraction 22; other authors (25,30,44,51) report that the glands experience a greater
volume loss in the first half of treatment; Sanguineti et al (28) report that 60 % of total parotid
gland volume loss occurs in the first half of treatment; and Bhide et al (11) report the largest
parotid gland volume reduction of 14.7 % occurred between week 0 and 2.
Some investigators have reported the ipsilateral (or irradiated) versus contralateral (or spared)
parotid gland volume reduction in those patients with well-lateralised tumours. It is generally
11

accepted that the ipsilateral gland demonstrates greater volume reduction than the contralateral
gland (12,20–22,34,35,39,41,52,53), as the spared gland would receive a lower dose; however
Fiorentino et al (47) report similar volume loss for both ipsilateral and contralateral glands. In
addition, the parotid gland volume may be affected by pre-chemotherapy hydration (54), therefore
it may be important to perform imaging studies at a consistent time with respect to chemotherapy
delivery.
The geometric movements of parotid glands have also been measured by numerous investigators.
This has been measured by calculating the shift of the centre of mass of the entire gland (10–
12,24,52), or it’s medial and lateral edges (24,30,32,33,50), in relation to a reference point. Others
have also measured the distance between the centre of mass of the right and left parotid glands
(26,44), to determine if they move closer to each other (i.e. displace medially). Regardless of the
measurement method used, a medial displacement of the parotid glands has been demonstrated
during the course of radiation therapy (10–12,25,26,30,33,44,48,52,55); with Barker et al (10)
reporting a 3.1 mm, and Castadot et al (12) reporting a 3.4 mm mean medial displacement at the
end of radiation therapy. Two investigators (26,44) report a reduction in the distances between the
centre of mass of the right and left parotid glands, indicating a medial displacement of the glands;
by a mean of 4.9 to 5.2 mm. Jensen at al (52) stated that parotid glands displaced cranially and
dorsally, as well as medially, however the magnitude of this displacement has not been reported by
them.
This shift is most likely due a displacement of the lateral portion of the gland (where the main mass
of the gland is situated); rather than the medial portion. Marzi et al (32) report that the lateral
aspect of the parotid gland showed a medial displacement of 6.5 4.7 mm, whereas the medial edge
had only a 0.8 5.1 mm medial displacement. Similarly, Vásquez-Osorio et al (34) report the lateral
portion of the gland demonstrating a significant 33 mm medial shift, compared to a 13 mm
medial shift of the medial portion; and Other authors also report that the lateral, but not medial,
portions displace medially (24,30,50). The fact that the lateral portion of the parotid gland shows
greater medial displacement than the medial portion, would suggest that most of the volume loss of
the parotid glands described above would be occurring in the lateral potion of the gland; a view
which is also supported by Robar et al (50).
Similar to their finding relating to parotid gland volume, Kagar at al (54) report that parotid gland
displacement may also be affected by pre-chemotherapy hydration, with a lateral displacement
seen in the immediate days following chemotherapy administration and a medial displacement
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observed thereafter. This highlights the importance of consistent timing of imaging studies with
respect to chemotherapy delivery. Additionally, the displacement direction and magnitude may
vary due to set-up uncertainties and varying magnitudes of displacement in varying directions in
different patients.

2.3.2 Submandibular Gland
There is less reporting of changes to submandibular gland volume and position during the course of
radiation therapy. This is most likely due to the fact that both submandibular glands are usually
within the high dose region and therefore it is often not possible to spare appreciable dose to these
glands during treatment planning. However, the submandibular glands are responsible for much of
the resting (unstimulated) salivary function (56) and where possible should be spared (without
impacting on tumour coverage) in order to reduce later complications.
Brouwer et al (48) reports an average volume reduction of 22 %, when combining the results of
several studies. A reduction of volume between 11 and 37 % has been reported in other
publications (19,22,34,45). Vásquez-Osorio et al (34) report an 11 % reduction in contralateral (or
spared glands), smaller than a 20 % reduction for ipsilateral (or irradiated) glands; Castadot et al
(12) report a similar finding with regards to ipsilateral and contralateral glands. Wang et al (45)
demonstrate that there is a greater volume loss in the first half of treatment (11 %) compared to
the second half of treatment (6 %).
The submandibular glands demonstrate a general superior displacement during the course of
radiation therapy of 3 to 4 mm (48). The ipsilateral gland demonstrated a greater magnitude of
shift than the contralateral gland; with Castadot et al reporting a mean 2.7 mm and 1.7 mm shift for
the ipsilateral and contralateral glands respectively (12). The authors also noted that the ipsilateral
gland also demonstrated as medial displacement of 1.7 mm. Similarly, Vásquez-Osorio et al (34)
report that the ipsilateral glands demonstrate a larger superior displacement, of 3 to 4 mm, than
the contralateral glands, 1 to 2 mm.
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2.3.3 Swallowing Structures
Cozzolino et al (46) report a 13 % increase in larynx volume during postoperative radiation
therapy. Similarly, Ricchetti et al (22) report significant volume increase of the constrictor muscles
and larynx at the end of radiation therapy, due to oedema in these structures; whereas other
muscles and the thyroid gland exhibited a reduction in volume. Similar findings have been reported
by Brouwer et al in their review paper (48). In an MRI-imaging study, Popovtzer et al (57) report
volume increase in the pharyngeal constrictor muscles, due to oedema, especially in areas that
received >50 Gy of dose. Changes in the swallowing structures were not specifically investigated in
this study.

2.3.4 The Neck
Whilst the external contour of the “neck” is not considered an organ at risk; the anatomical change
in neck contour is of interest, as it would be affected by weight loss, muscle atrophy and tumour
mass reduction. A reduction in volume within the external skin contour has been reported during
radiation therapy (10,19,42), the extent of which correlates with the weight loss in the patient
(10,19). Another method of evaluating changes in the “neck” has been to quantify the transverse
neck diameter, or skin separation; this parameter also shows a reduction in size during radiation
therapy (18,24,27,38) and similarly shows a correlation with weight loss.

2.4 Dosimetric Changes to Tumour Volumes Occurring during
Radiotherapy for Head and Neck Cancer
Section 2.2 reviews the volume changes occurring in the delineated tumour volumes (GTV, CTV,
PTV) during radiation therapy. These changes would be expected to alter the dose distribution to
the tumour target volumes from what has been planned; with inadequate dose delivery potentially
compromising tumour control probability. There is variability in reporting of dose to tumour
volumes; with some investigators reporting dose to PTV and others to CTVs or GTVs. Additionally,
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the Dose-Volume Histogram (DVH) measures quantified also varies; e.g. V98 (Volume receiving ≥98
% of the prescription dose), V95 (Volume receiving ≥95 % of the prescription dose) and minimum
dose are some measures reported. This makes it challenging to directly compare studies.
In terms of PTV coverage, some investigators report a reduction in dose to the PTV structures
during the course of radiation therapy (11,18,29,42,53). Reduced dose homogeneity within the PTV
is also reported (11,18,20,29). Other investigators, however, report that the PTV is not significantly
underdosed (20,24–26,40). Castadot et al (58) report a 2 Gy dose reduction to the high dose PTV,
but the low dose PTV experiences <0.2 Gy reduction. Ahn et al (18) report reduced coverage of the
PTV of the nodal region, but not the PTV of the primary tumour.
Zhao et al (35) and Zhang et al (41) report underdosing of the CTV volume during the RT course,
however other investigators report that the CTV is not underdosed as a result of the anatomical
changes occurring (23,37,40,46,58,59). The GTV is not underdosed during the course of RT
(31,32,59); which seems logical, as the GTV is the smallest volume which tends to reduce in size,
and from which the CTV and subsequently PTV are constructed, and therefore would be least
affected by anatomical variations.

2.5 Dosimetric Changes in Organs At Risk Occurring during
Radiotherapy for Head and Neck Cancer
2.5.1 Parotid Gland
In section 2.3.1, volume loss and medial displacement of parotid glands have been discussed. IMRT
planning functions to sculpt the dose around the parotid glands in order to reduce dose to the gland
whilst maintaining tumour dose coverage; as the parotid glands and PTV volumes are in close
proximity and may even overlap. Medial displacement potentially moves the parotid glands into the
high dose region, with dose delivery differing to what was originally planned.
Different measures are used to report parotid gland dosimetry, including mean dose, V26 (Volume
receiving ≥26 Gy), V30 (Volume receiving ≥30 Gy) and D10 (minimum dose to 10 % of the volume);
however the most commonly used metric is the mean dose. In addition, dose to the parotid glands
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is measured at various time points of radiation therapy. The literature consistently demonstrates
that the parotid glands receive a higher dose than was originally planned; this ranges from 0.92 to
5.6 Gy increase in dose in different papers (11,18,20,24–26,29,32,33,38,40,41,44,46,53,60,61).
Brouwer et al (48), in reviewing multiple papers report the average increase in mean dose during
radiation therapy as 2.2 2.6 Gy. A dose increase occurs early in the treatment course; with
significant changes occurring from fractions 10 and onwards (18,24,46). The large variability
between the studies though, may be due to several factors, including the site of the disease, IMRT
beam arrangement and daily set-up factors. Hunter et al (61) noted that there was individual
patient variability in dose to the parotid glands, with some glands showing an increase in dose, and
others a reduction in dose. However, in all glands where a reduction in dose was noted, the
contralateral gland had an increased dose; suggesting that patient rotation at set-up may have
influenced the outcome. They report an overall average increase in mean parotid dose of 0.92 Gy;
but in those glands which had an increase in mean dose (i.e. excluding the glands with a dose
reduction), this was in the magnitude of 2.2 Gy. Robar et al (50) demonstrated that there was an
average increase in mean dose in only the left parotid gland, suggesting that disease location and
IMRT beam arrangement may also have influenced the dose deposition in the parotid glands.
Hansen et al (42) also demonstrated a discrepancy between dose of the right and left parotid
glands.
Castelli et al (38) report that there was an increase in parotid gland dose beyond acceptable dose
constraints in 59 % of cases, leading to an increase in xerostomia risk by 8 % using NTCP modelling.
When comparing the ipsilateral (or treated) versus the contralateral (or spared) parotid gland, the
ipsilateral gland receives a significantly increased dose compared to the contralateral gland;
Fiorentino et al and Bhide et al both report significant increases in parotid gland dose in the
ipsilateral glands only (11,60); whereas Cheng et al (20) report the increase in dose to the
ipsilateral and contralateral glands being 34 % and 10 % respectively. Loo et al (39) however
report the opposite trend, with contralateral parotid glands receiving a greater increase in mean
dose than the ipsilateral glands; however they state that the whole gland was not imaged in all
cases, as dose was calculated on parotid glands identified on Cone Beam CT images.
A small number of investigators have reported that the parotid gland dose does not significantly
increase during radiation therapy (21,31); however in the study by Height et al (31) only 4 patients
had lymph node disease in the neck and this may have affected their results. In the study reported
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by Ho et al (21), most patients had either received neoadjuvant chemotherapy to reduce bulky
disease in the neck or had undergone a neck dissection prior to radiation therapy.

2.5.2 Spinal Cord and Brainstem
Some investigators have studied the impact of anatomical changes during RT on the dose delivery
to the spinal cord and brainstem. All studies have assessed the maximum dose (Dmax) to the spinal
cord and many have also reported the highest dose to 1 cc (D1cc) of the spinal cord; although there
is a variation in the timings of repeat imaging for dose calculations. Other measures, include highest
dose to 2 cc (D2cc) in relation to the spinal cord and highest dose to 1 % of volume (D1%) in
relation to the brainstem. In general, the spinal cord receives a higher Dmax than was originally
planned; ranging from 1.2 to 2.5 Gy increase in dose (18,20,21,24,29,35,53). Ahn et al (18) report
that 30 % of their patient cohort (7 of 23) exceeded spinal cord tolerance dose; whilst Cheng et al
(20) report 11 % (2 of 19) of their patient cohort exceeded spinal cord tolerance dose at 30 and 50
Gy. Whilst not finding an increase in spinal cord Dmax, Nishi et al (33) report an average increase of
1.9 Gy in the D2cc of the spinal cord. Qi et al (26) report a Dmax increase of 3 Gy, but this was not a
statistically significant value in their patient cohort. Increase in spinal cord dose can occur in the
first half of treatment (24,35), with Huang et al (25) reporting statistically significant increases
from fraction 5.
Increase in brainstem delivered dose has been reported only in studies of patients with
nasopharyngeal cancer; with an average increase in Dmax between 0.2 and 2.7 Gy (20,24,25,35,59).
Cheng et al (20) report 11 % and 16 % of their patient cohort exceeded brainstem tolerance dose at
30 and 50 Gy respectively. Zhang et al (59) report that whilst maximum spinal cord dose remained
within the dose constraints, the brainstem maximum dose exceeded dose constraints in 20 % of
patients. Similar to spinal cord, an increase in brainstem dose occurs in the first half of treatment
from as early as fraction 15 (20,24,25,35).
Spinal cord and brainstem dose delivery can be impacted by daily set-up variations; Han et al (49)
demonstrated an increase in spinal cord Dmax of up to 0.5 Gy if daily set-up corrections were not
undertaken.
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2.5.3 Other OARs
The difference between planned and delivered dose has been less well-studied in other OARs;
therefore findings are more sparse and inconsistent.
Castadot et al (58) report a 0.9 Gy increase in mean dose delivered to the submandibular glands.
They also report that the doses to larynx and mandible were not elevated, but there was a small
increase of 0.7 Gy in delivered mean dose to the oral cavity as a result of anatomical changes. An
increase in oral cavity dose was reported by Beltran et al (53); by contrast Ho et al (21) report no
significant changes in mean doses to the larynx and oral cavity. Cozzolino et al (46) report an
increase in laryngeal dose, but the dose remained within the planning dose constraints. Some
investigators report no significant changes in mandible dose (40,42,53), though Cheng et al (20)
report an increase in mean mandible dose. Cheng et al also report increase in Dmax dose to the
optic nerve and ipsilateral eyeball in their cohort of patients being treated for nasopharyngeal
cancer. Huang et al (25) in their cohort of nasopharyngeal carcinoma patients report inconsistent
variable dose increase to the glottis, eyes and lens. They also report no significant differences
between planned and delivered doses to the temporal lobes, optic nerves, optic chiasm, cochleae,
mandible, oral cavity, supraglottis and subglottis. No conclusion can be made from these data as the
measures are not comparable.

2.6 Clinical Impact of Dosimetric Changes during Radiation
Therapy
Normal tissue complications from radiation therapy can have a significant effect on the Quality of
Life of a patient (62). Dose volume effects have been described in the literature with respect to
significant OARs for head and neck radiation therapy, i.e. the parotid and submandibular glands,
spinal cord, brainstem and swallowing structures. For the salivary glands, increased dose to the
parotid and submandibular glands leads to an increased incidence and severity of xerostomia;
which can have a lasting impact on dental hygiene, risk of oral infections and difficulties with
chewing and swallowing (56,63,64), as well as adversely affecting Quality of Life (65). Increased
swallowing complications, including dysphagia, stricture and aspiration, and subsequent Quality of
Life impact are observed with higher doses to the larynx and constrictor muscles (66–71).
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Dose constraints have been developed, based on clinical studies looking at dose-volume effects, and
published in the QUANTEC papers (56,68,72,73). These analyses are often based on retrospective
data in heterogeneous patient populations, using different treatment techniques, margins and dose
prescriptions and with differing end-points; therefore these are limitations to consider in the
interpretation of these dose constraint measures (5,74). Additionally, dose-volume data are derived
from dose-volume histograms of planned dose distributions and do not take into account the
dosimetric impact of anatomical changes occurring during radiation treatment. Nevertheless, these
studies are the best information we currently have; hence widely used to guide radiation treatment
planning.
More recently, some investigators have reported dose effects on radiation toxicity and Quality of
Life based on delivered doses (rather than planned dose delivery), although the literature is limited.
An increase in delivered dose to the parotid glands is associated with increased xerostomia risk,
using Normal Tissue Control Probability (NTCP) modelling (32,38). Hunter et al (61), in comparing
planned versus actually delivered parotid gland dose on salivary output, report that the delivered
parotid gland dose did not correlate better with saliva production than the planned parotid gland
dose. However, if the delivered dose was ≥ 0.1 Gy more than planned dose on day one of treatment,
this correlated with a ≥4 Gy increase in delivered dose to the parotid glands than planned. Zhao et
al (35) conducted a retrospective matched case-control study comparing outcomes in patients who
had their IMRT plans adapted at fraction 15 to those who did not undergo plan adaptation. Patients
whose plans were adapted received lower dose to their parotid glands and subsequently
experienced lower xerostomia severity. In a prospective case-control study, 89 nasopharyngeal
cancer patients who underwent plan adaptation at fraction 15 or 25, had improved global and
symptom specific Quality of Life scores compared to the 43 patients who did not have plan
adaptation, though dosimetric analysis was not performed in this study (75).

2.7 The Benefit of Adaptive Radiation Therapy in Head and
Neck Cancer Patients
The previous sections have explored the morphological changes occurring in patients during
radiation therapy; and the subsequent impact on the delivered dose to target volumes and organs
at risk. This can have a clinical impact in terms of radiation toxicity and Quality of Life, as well as a
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potential impact on tumour control probability. Therefore patients may benefit from an ART
approach; whereby a new treatment plan is created during the course of radiation therapy to
account for the morphological changes which have occurred. This section reviews the literature on
the impact of ART.

2.7.1 Impact of ART on Tumour Dose and Clinical Outcome
The data on the impact of ART on tumour dose and outcome are summarised in Table 2.1; the
results showing variability in benefit. Improved tumour target volume coverage, in terms of dose
and dose homogeneity, occurs with plan adaptation in some studies (18,35,41,52,58,76). Ahn et al
(18) conducted a prospective study of 23 patients undergoing chemoradiotherapy for HNC. The
radiotherapy prescription was 66 to 69.6 Gy in 33 fractions to the primary PTV, with lower doses to
at risk and low risk nodal regions. The primary PTV was then boosted to 72 Gy; with a total number
of 40 fractions. Re-imaging with planning CT scans was performed at fractions 11, 22 and 33.
Tumour and OAR criteria were specified for triggering a plan adaptation; specifically PTV D95 less
than 95 % of prescription dose, Dmax >45 Gy for the spinal cord, D50>26 Gy for the parotid glands,
brainstem V54 >20 % and mandible V60 >10 %. Of the 15 patients (65 % of the cohort) who
benefited from plan adaptation, 14 received a benefit in PTV coverage and dose homogeneity,
though the extent of benefit has not been quantified in the paper. The benefit to organs at risk is
described in the section 2.7.2.
Castadot et al (58) compared the planned, delivered and adapted dose distributions at four time
points in their cohort of 10 patients undertaking chemoradiotherapy to a dose of 69 Gy over 30
fractions. Re-imaging was undertaken with contrast-enhanced CT scans and manual contouring of
the regions of interest was performed. Though their patients did not receive the actual adapted
plans, a small but significant improvement in coverage of the low dose PTV and CTV was reported;
in contrast the adapted doses to the high dose PTV and CTV were actually lower than the delivered
dose. The authors suggest that this may have been due to a volume reduction in the high dose CTV
and PTV volumes. Zhang et al (41) report, in their study of 13 patients with oropharyngeal cancer,
that the high dose CTV coverage was improved with weekly plan adaptations.
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Jensen et al (52) took a different approach, whereby dose calculation and plan adaptation was only
undertaken if there was a ≥1 cm discrepancy in contours over a minimum of 3 CT slices, during
weekly imaging in 72 patients. 15 patients (21 %) underwent plan adaptation; with a higher
proportion of the plan adaptations occurring in patients with nasopharyngeal or hypopharyngeal
tumours. Due to the study design, they only report on the dosimetric outcome of those patients who
underwent plan adaptation, as dose calculations were not performed on all patients. In these
patients, plan adaptation resulted in improved nodal volume coverage, especially in the lower neck.
There are some investigators who have reported no benefit with plan adaptation in terms of
tumour dose (23,24,27,40,59,77); though the organs at risk did benefit from the plan adaptations
that were performed (section 2.7.2). One of these studies does not specify which tumour target
volume was being investigated and two of these studies look at dose to the CTV +/- GTV (23,59). It
would be expected that there is more acceptable dose coverage to the CTV than when examining
dose to the PTV, as the CTVs should be situated well within the high dose area with a larger
distance to regions of steep dose gradient. However, it should be noted that Schwartz et al did not
add an expansion margin for PTV when undertaking adaptive planning (23). By contrast, Wang et
al (76) report an improvement in coverage of the CTV (high dose) and GTV with plan adaptation at
fraction 25; with percentage coverage of the CTV increasing by 4.9 % to 91.6 % with replanning.
There are only three studies reporting clinical outcomes as a result of ART in head and neck cancer
patients. Two of these are prospective studies, and despite there being selection bias in both
studies, the results are still worth noting. Yang et al (75) conducted a prospective study in 129
patients with nasopharyngeal cancer. Their patients were offered a repeat CT scan at fraction 15 or
25 (or both) and the treatment plans were adapted to the new anatomy. 89 patients underwent
repeat imaging, and their outcome data are compared to the outcomes of the 43 patients who
refused repeat imaging. Those patients whose plans were adapted had a small but significant
improvement in two year local regional control compared to the patients who did not have plan
adaptations; 97 vs. 92 %. There was no difference in two year overall survival rates between the
groups. The dosimetric difference between the two groups was not reported. Similarly, Chen et al
(78) conducted a prospective study of 317 patients with head and neck cancer, undergoing
definitive or adjuvant radiation therapy. Patients received plan adaptations if requested by the
treating physician; based on a clinical assessment of weight loss, tumour shrinkage, mask fitting or
if the patient had a prolonged treatment break. The patients selected for ART had significantly
different characteristics (indicating selection bias) in that they were more likely to be receiving
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definitive (rather than adjuvant) treatment and therefore also more likely to be receiving
concurrent chemotherapy (p= 0.01) . The patients selected for ART were also more likely to have
higher tumour (T) and nodal (N) tumour classification; though this was non-significant. Of the 51
(16 %) patients who underwent ART, there was superior two year local regional control than the
unadapted patients; 88 % vs. 80 %; despite these patients tending to have more advanced disease.
There were no differences in overall survival rates.
In a retrospective case-controlled study, Zhao et al (35) investigated the effect of plan adaptations
on 33 patients with nasopharyngeal carcinoma, who underwent repeat imaging at fraction 15 with
plan adaptation. Their dosimetric and clinical outcomes were compared to a historical cohort of 66
patients undergoing the same treatment without plan adaptation. In those patients with T3 or T4
tumours, plan adaptation resulted in improved three year progression free survival rates of 73 %
vs. 68 % for the unadapted cohort; with a median progression free survival benefit of two months
(50 months vs. 48 months). From a dosimetric perspective, plan adaptation resulted in improved
coverage of the CTV.
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Study

N

RT dose
(Gy)

Timing of
imaging

ART effect

Adaptive plan
trigger

Patients
treated
with ART
Y

Ahn et al,
2011 (18)

23

72

F11,22,33

 14/23 (61 %) benefit in PTV coverage
and dose homogeneity

If exceed dose
constraints

Capelle et al,
2012 (27)

20

66

F15

 Decr D1 for high dose PTV 0.3 Gy
 Decr D1 for low dose PTV 0.6 Gy

All scans

Y

Castadot et al,
2011 (58)

10

69

14.2, 24.5, 35.0,
44.9 Gy

 Incr D95 for low dose PTV 0.4 Gy + CTV
0.3 Gy
 Decr in D95 for high dose PTV 4.6 Gy +
CTV 3.1 Gy

All scans

N

Chen et al,
2014 (78)

317

66

At clinician
discretion

 Incr 2yr LRC 88 % vs. 80 %
 No effect on 2 yr OS

At clinician
discretion

Y

Hansen et al,
2006 (42)

13

70

If tumour
shrinkage &/or
weight loss

 Incr D95 for high dose PTV 2.2 Gy + low
dose PTV 3 Gy

All scans

Y

Jensen et al,
2012 (52)

72

66 to 72

Weekly

 15/72pts (21 %) underwent ART
 More ART events in pts w NPC and HPX
ca
 Improved coverage of elective LN
volumes 3.7 % and supraclavicular nodal
area 8.3 %

If contour
deviation ≥1 cm
on 3 CT slices

Y

Schwartz et al, 22
2012, 2013
(23,77)

66 to 72

Weekly

 All pts had 1 replan; 8/22pts (36 %) had
2
 No benefit to CTV coverage

All scans + if
significant
discrepancy of
contour overlays

Y

Wang et al,
2010 (24)

66

F18

 No benefit to PTV coverage

All scans

N

15

23

Wang et al,
2010 (76)

28

70-76

F25

 Incr % of prescription dose to high dose
CTV by 4.9 %
 Incr % of prescription dose to GTV by 7.8
%

All scans

Y

Wu et al, 2009
(40)

11

70

Weekly

 “Minimal effect on target volume
coverage”

All scans

N

Yang et al,
2013 (75)

129

70 to 76

F15, 25 or both

 Incr 2yr LRC 97 % vs. 92 %
 No effect on 2 yr OS

All scans

Y

Zhang et al,
2012 (59)

11

69.96 to
73.92

Weekly till
week5

 No benefit to GTV + CTV coverage

Week 5

N

Zhang et al,
2016 (41)

13

70

Weekly

 Incr high dose CTV D98

All scans

Y

Zhao et al,
2011 (35)

33

70

F15 (mean)

 Incr CTV D95
 Incr 3yr local PFS in T3/4 pts 73 % vs 68
% (compared to matched case-control)
 Incr median PFS from 48 to 50 months

All scans

Y

Table 2.1. Studies reporting on effect of plan adaptation on target volume coverage and clinical tumour outcomes
N- number of patients, RT- radiation therapy, Gy- Gray, ART- Adaptive Radiation Therapy, F- fraction, Incr- increase, Decr- decrease, Yyes, N-no, PTV- Planning Target Volume, CTV- Clinical Target Volume, GTV- Gross Tumour Volume, NPC- nasopharyngeal carcinoma, HPXhypopharyngeal carcinoma, LN- lymph node, LRC- local regional control, OS- overall survival, QoL- Quality of Life, D95- minimum dose to
95 % of volume, D98- minimum dose to 98 % of volume, D1- maximum dose received by 1 % of the volume, PFS- progression free
survival.
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2.7.2 ART Impact on Organ At Risk Dose and Clinical Outcome
The data on the impact of ART on OARs are summarised in Table 2.2; the majority of studies
reporting the impact on parotid glands, with fewer reporting on spinal cord and brainstem dose.
Almost universally, adaptive planning results in improved dose distribution to the parotid glands
and spinal cord, compared to no adaptation.
Ahn et al (18) report that 15 of 23 patients (65 %) benefited from plan adaptation; seven of them
had an improvement in spinal cord dose, five in parotid gland dose and 14 experienced tumour
dose coverage improvement. Similarly, Wang et al (76), in a study of 28 patients undergoing
treatment for nasopharyngeal carcinoma using the RTOG0225 protocol and imaged at fraction 25,
reported that 14 of 28 (50 %) of plans were non-compliant for OAR dose constraints. 11 plans
exceeded brainstem, six exceeded spinal cord and four exceeded parotid gland dose constraints.
Adaptive planning subsequently reduced the dose to these OARs. Castelli et al (38) conducted a
prospective investigation of weekly non-contrast CT imaging and looked at the potential effect of
plan adaptations. 11 of 15 patients (73 %) would have benefited from ART in terms of parotid gland
dose. In those patients whose parotid gland experienced overdosing, weekly replanning would have
reduced the mean dose to a similar value (or less) than the pre-treatment planning level. A 5.1 Gy
reduction in mean dose was observed in the overdosed parotid glands; whilst a smaller but still
significant 1.4 Gy mean dose reduction was observed in the non-overdosed glands.
Zhang et al (41), in a prospective study, quantified the impact of different ART strategies (in terms
of frequency and timing) on parotid gland dose delivery. Increasing the frequency of plan
adaptations resulted in progressive improvement in parotid gland dosimetry; weekly plan
adaptation reduced the mean parotid gland dose by 3.3 Gy (with a maximum benefit of 10.8 Gy).
However, a 3.1 Gy mean parotid gland dose reduction was achieved with three plan adaptations (at
weeks 1, 2 and 5), leading the authors to recommend a frequency of three plan adaptations as a
pragmatic approach with respect to dose benefit and resource allocation. Wu et al (40) performed a
retrospective study, investigating the effect that the number of plan adaptations would have on
parotid gland dose delivery. Whilst a single mid-treatment plan adaptation resulted in 3 %
reduction in parotid mean dose, the magnitude of benefit increased with the number of plan
adaptations; 5 % for two adaptations and 8 % for six weekly adaptations.
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A benefit in terms of dose reduction to OARs is worthwhile achieving only if it translates into a
clinical benefit. However, the literature available is sparse, with small patient numbers and each
individual investigation having its limitations. Castelli et al (38) report that a reduction in mean
parotid gland dose of 5.1 Gy would reduce xerostomia risk by 11 %, using NTCP modelling. Their
investigation did not treat the patients with adapted plans and therefore they report only a
theoretical outcome. Yang et al (75) report, in a non-randomised study of 129 patients, a Quality of
Life improvement with the use of ART. This included both global and head and neck specific Quality
of Life scores. The limitations of their study have been discussed in section 2.7.1 above. However, in
their retrospective case-matched review of 33 patients, Zhao et al (35) note that whilst a reduction
in parotid gland dose coverage was observed, this did not translate to significant improvements in
early or late toxicity scores. However, this study also has methodological limitations; it is nonrandomised and evaluation is retrospective.
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Study

N

RT dose
(Gy)

Timing of
imaging

ART effect

Adaptive plan
trigger

Patients
treated
with ART
Y

Ahn et al,
2011 (18)

23

72

F11,22,33

 5/23 (22 %) benefit in PG sparing
 7/23 (30 %) benefit in SpC dose

If exceed dose
constraints

Capelle et al,
2012 (27)

20

66

F15

 Decr SpC Dmax 0.4 Gy
 Decr PG Dmean 0.6 Gy (NS), V26 3.8 %
(NS)

All scans

Y

Castadot et al,
2011 (58)

10

69

14.2, 24.5, 35.0,
44.9 Gy

 Decr in D2 for SpC + Dmean for oral
cavity
 No significant benefit for PG, SMG,
mandible + larynx

All scans

N

Castelli et al,
2015 (38)

15

70

Weekly

 Decr PG Dmean 5.1 Gy (overdosed PG),
1.4 Gy (non-overdosed PG)
 Decr xerostomia risk 11 % in overdosed
PG

All scans

N

Hansen et al,
2006 (42)

13

70

If tumour
shrinkage &/or
weight loss

 Decr PG Dmean 2.9 Gy (R) 0.2 Gy (L) (NS) All scans
 Decr PG V26 10 % (R); incr 0.7 % (L)
(NS)
 Decr Dmax 4 Gy SpC + 2.6 Gy BS
 Decr D1cc 3.1 Gy SpC + 2.3 Gy BS (NS)
 Decr Dmax mandible 1.4 Gy

Y

Jensen et al,
2012 (52)

72

66 to 72

Weekly

 15/72pts (21 %) underwent ART
 More ART events in pts w NPC and HPX
ca
 Decr in PG Dmean 3.9 % ipsi, 11.5 %
contra

If contour
deviation ≥1 cm
on 3 CT slices

Y

Kuo et al,
2006 (55)

10

72

45 Gy

 Decr PG Dmean 3 Gy (L) 3.2 Gy (R)

All scans

Y
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20

60 to 70

Week 3 or 4

 Decr PG Dmean 10.3 Gy
 Decr SpC D2 2.4 Gy (marginally
significant)

All scans

Y

Schwartz et al, 22
2012, 2013
(23,77)

66 to 72

Weekly

 All pts had 1 replan; 8/22pts (36 %) had
2
 1 replan- Decr PG Dmean 0.6 Gy contra,
1.3 Gy ipsi
 2 replan- Decr PG Dmean 0.8 Gy contra,
4.1 Gy ipsi

All scans + if
significant
discrepancy of
contour overlays

Y

Wang et al,
2010 (24)

15

66

F18






Decr PG Dmean 1.3 Gy (R) 1.4 Gy (L)
Decr PG V26 5.4 % (R) 5.7 % (L)
Decr Dmax 3 Gy SpC + 1.9 Gy BS
Decr D1cc 2.6 Gy SpC + 1.4 Gy BS

All scans

N

Wang et al,
2010 (76)

28

70-76

F25






Decr PG Dmean 3.2 Gy (R) (NS) 4.2 Gy (L) All scans
Decr PG V30 11.5 % (R) 8.1 % (L)(NS)
Decr Dmax by 5 Gy SpC
Decr Dmax by 4 Gy BS (NS)

Y

Wu et al, 2009
(40)

11

70

Weekly

 1 replan- Decr PG Dmean 3 %
 2 replans- Decr PG Dmean 5 %
 6 replans- Decr PG Dmean 8 %

All scans

N

Yang et al,
2013 (75)

129

70 to 76

F15, 25 or both

 Improved global and H+N specific QoL

All scans

Y

Zhang et al,
2012 (59)

11

69.96 to
73.92

Weekly till
week5

 Decr PG Dmean 3.8 Gy (R) 5.3 Gy (L)
 NS decr SpC Dmax 3 Gy, D1 1.2 Gy
 NS decr BS Dmax 5.9 Gy, D1 6.2 Gy

Week 5

N

Zhang et al,
2016 (41)

13

70

Weekly

 Decr PG Dmean by a mean/maximum
value of:

All scans

Y

Nishi et al,
2012 (33)

28







Zhao et al,
2011 (35)

33

70

F15 (mean)

1 ART 2.2/10 Gy
2 ART 2.9/10.6 Gy
3 ART 3.1/11 Gy
4 ART 3.2/10.8 Gy
5 ART 3.3/10.8 Gy
6 ART 3.3/10.8 Gy

 Decr PG Dmean
 Decr Dmax SpC + BS
 NS difference in early/late toxicity

All scans

Y

Table 2.2. Studies reporting on effect of plan adaptation on OAR coverage and clinical outcomes
N- number of patients, RT- radiation therapy, Gy- Gray, ART- Adaptive Radiation Therapy, F- fraction, PG- parotid gland, SpC- spinal cord,
Incr- increase, Decr- decrease, D2- minimum dose to 2 % of volume, Dmean- mean dose, SMG- submandibular gland, NPC- nasopharyngeal
carcinoma, HPX- hypopharyngeal carcinoma, ipsi- ipsilateral, contra- contralateral, R- right, L- left, BS- brainstem, V26- volume receiving
26 Gy, V30- volume receiving 30 Gy, Dmax- maximum dose, D1cc- dose to 1 cc of volume, NS- statistically non-significant, H+N- head and
neck, QoL- Quality of Life, D95- minimum dose to 95 % of volume, PFS- progression free survival.
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2.8 Implementation of ART for Head and Neck Cancer Patients
2.8.1 Clinical Resource Impact
The clinical implementation of an ART protocol for HNC patients, using multiple repeat CT scans, is
a resource intensive process. On average, the time taken to manually contour the required
anatomical structures, in the head and neck region, is over two hours (79–81). Additional time and
labour is required for dosimetry calculation, with subsequent plan generation and Quality
Assurance procedures if a plan adaptation is implemented.
Furthermore, not all patients may benefit from treatment plan adaptation, with the proportion of
patients who experienced a dosimetric benefit varying widely (18,23,38,52,76). Ahn et al (18), who
imaged at three time points during the treatment course, demonstrated that 65 % of their patients
(15 of 23) required replanning. 14 of the 15 patients (61 %) with inadequate plans had insufficient
PTV coverage, 7 (30 %) and 5 (22 %) exceeded spinal cord and parotid gland dose constraints
respectively. Wang et al (76), using a single re-imaging, reported that 50 % of unadapted plans
were noncompliant for OAR dose criteria. Jensen et al (52) report that 21 % of their cohort
underwent plan adaptation, however this decision was based on an assessment of differences in
contour overlay, rather than a dosimetric evaluation.
In the study by Schwartz et al (23), all 22 patients appeared to require at least one replan due to
“CTV and normal tissues changes”. Since underdosing of the CTV was not observed, they suggest
that plan adaptation was required due to excessive OAR dose. This is a higher rate of plan
adaptations required than other reports; it may be due to the frequency of CT scanning and
dosimetric analysis (weekly) being more frequent in this patient cohort. Castelli et al (38) also
conducted weekly CT imaging, specifically investigating the parotid gland dose delivery. They
report that 11 of 15 patients (73 %) would have benefited from ART in terms of parotid gland dose.
Therefore, in terms of the most appropriate allocation of limited resources, the ability to identify
those patients who would most benefit from the ART process is highly relevant. Equally important
is the determination of the best timing for ART.
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2.8.2 Factors Which Correlate with Inadequate Dose Delivery
In order to best allocate limited resources, the recognition of patients who would gain most benefit
for ART is extremely beneficial. In an ideal setting, easily measurable surrogate measures of
inadequate plan dosimetry would allow for a patient’s treatment plan to be efficiently assessed and
reoptimised.
Investigators have reported correlations of plan dosimetry with factors such as weight loss,
changes in tumour volume and parotid gland volume, initial volume of parotid glands and medial
parotid gland displacement; these are summarised in Tables 2.3 to 2.5. The correlations with
parotid gland (Table 2.3) and spinal cord dose (Table 2.4) have been most frequently reported,
however, some data regarding submandibular gland, tumour volume, brainstem and mandible dose
are also available (Table 2.5). It is impossible to draw strong conclusions from these reports, as the
investigations often involve small patient populations, with the identification of measures of plan
inadequacy not being the primary objective of the study. Although statistically significant findings
are reported, correlations are often weak and no single factor stands out from the numerous
correlations reported. A factor found to be correlated with inadequate dose delivery in one report,
may not be significantly correlated in another report. Additionally, different statistical measures
have been used to describe associations, and the variability of tests makes it difficult to directly
compare different papers.
Despite these limitations, some investigators have attempted to generate models to predict
whether a patient requires plan adaptation. Castelli et al (82) generated a nomogram, based on the
data of 20 patients, to predict parotid gland dose. They report that their nomogram has a sensitivity
of 80 %, specificity 60 %, positive predictive value 86 % and negative predictive value of 50 %. In
patients who were identified with overdose to the parotid glands, using this nomogram, plan
adaptation resulted in a reduction in mean parotid gland dose of 3.9 Gy and a resultant reduction of
xerostomia risk of 8 %.
Brown et al (83) have also proposed a model to predict the need for plan adaptation, based on the
tumour site, nodal stage at diagnosis, patient weight and initial nodal size. Patients are classified
into low, intermediate and high risk groups, with a >80 % probability of requiring plan adaptation
in high risk patients and 60-80 % probability in intermediate risk patients. This model was
developed based on a study of 110 patients, who underwent CT imaging at fraction 15. Based on
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target volume and OAR coverage, a decision to undertake plan adaptation was made. Of the 100
patients, only 5 required plan adaptation at fraction 15, which is a small proportion compared to
the frequency in other studies mentioned in section 2.8.1.
Brouwer et al (84) took a different approach to the selection of patients for ART, based on the risk
of receiving >3 Gy excess in parotid gland dose. Whilst many factors were associated with change in
the mean dose to parotid glands on univariate analysis, only the planned mean parotid gland dose
was found to be significant on multivariate analysis. By selecting those patients with a mean parotid
gland dose of 22.2 Gy or above at planning, 76 % of parotid glands (ipsilateral or contralateral)
would be selected for plan adaptation. However, their model had a low positive predictive value of
19 %; i.e. only 19 % of the glands selected actually needed ART due to >3 Gy excess dose delivery.
The negative predictive value of their model was 81 %, suggesting that the model is best used to
identify those patients who would derive less benefit from plan adaptation. Whilst these models are
potentially useful tools, validation in larger patient cohorts should be performed.
The interfraction positional variation of patient anatomy also has a significant effect on dose
delivery (18,49,51,61). Ahn et al (18) report significant correlations between positional variation
and dose delivery to parotid glands, target volumes, spinal cord and mandible. Hunter et al (61)
found that if the delivered PG dose on day 1 was ≥0.1 Gy more than planned, this correlated with ≥4
Gy increase in delivered dose to the parotid glands at the end of radiation therapy. However,
rotational set up deviations, which could not be corrected for, also contributed to alterations in
dose delivery. In contrast, Capelle et al (27) report that there was no correlation found between
positioning variations and dose parameters. The movement of interstitial fluid could also cause
tissue deformation, with subsequent impact on dose (85).
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Study
Ahn et al,
2011 (18)

N
23

Parotid gland endpoint
D50 incr

Need for replan due to D50
overdose

Brouwer et al,
2016 (84)

113

Dmean change

Correlation parameter
Neck diameter decr at
mandibular joint
Neck diameter decr at
C1-5 level
PG vol decr
Weight loss
Isocentre displacement
Positional variation
(mandible level)
Neck diameter C2-3 level
Univariate analysis
BMI
Weight
T stage
N stage
Planned PG Dmean
Initial GTV volume
Tumour location,
Overlap of PG with PTV70
Age, surgery, initial PG
vol
Multivariate analysis
Planned PG Dmean

Capelle et al,
2012 (27)

20

Dmean

Neck thickness change at
mid-PTV level
GTV volume, weight
change, neck thickness at
C1 vertebra and thyroid
notch, T stage, N stage
33

Correlation/
Association
R 0.22-0.39

P value
ss but nr

R 0.15-0.28
R 0.22
R 0.30-0.35
nr
nr

0.002
0.001-0.006

nr

0.07-0.08
(ns)

R contra/ipsi
-0.32/-0.38
-0.24/-0.12
0.34/0.28
0.41/0.40
0.76/0.62
0.53/0.45
0.41/0.31
0.23/0.20
Nil found

contra/ipsi

R2 0.59/0.39

<0.001

R 0.64

<0.001

Nil found

0.002/<0.001

0.01/ns
<0.003
<0.0001
<0.0001
<0.0001
<0.001
0.02/0.03

Castadot et al,
2011 (58)

10

Improvement in Dmean ipsi
PG with ART
∆ Dmean planned +
delivered (contra PG)
Change in PG Dmean

Rate of GTV vol loss

R2 0.65

p= 0.005

Rate of contra PG vol loss

R2 0.62

p=0.006

Initial tumour vol, GTV
vol loss, inter-PG
distance

Nil found

PG overdose + ART benefit

CTV70 vol loss
Neck thickness reduction
PG vol loss

nr
nr
Nil found

p<0.01
p<0.01

Castelli et al,
2015 (38)

15

Castelli et al,
2016 (82)

20

PG overdose

CTV70 dose at planning
∆CTV dose at week1
Dmean PG at week1
∆PG Dmean at week1
PG Dmean week1/PG
Dmean week0

R2 0.32
R2 -0.46
R2 0.5
R2 0.72
R2 0.7

0.038
0.004
<0.01
<0.001
<0.01

Han et al,
2008 (49)

5

Delivered Dmean

PG vol

R -0.95

<0.01

Hunter et al,
2013 (61)

18

∆ Dmean planned +
delivered

∆ Dmean planned +
delivered on Day1
Weight change, initial PG
vol, PG vol loss

R 0.92

<0.001

Lee et al, 2008
(85)

10

∆ Dmean planned +
delivered

PG COM change
% weight change

R2 0.88
R2 0.58

nr
nr

Marzi et al,
2012 (32)

15

∆ Dmean planned +
delivered

∆ GTV vol
Initial PG vol, PG vol
change, planned PG
Dmean, initial GTV vol,
GTV vol change, weight
change

R 0.604
Nil found

0.017

Dmean
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Nil found

Qi et al, 2015
(26)

11

Vasquez
Osorio et al,
2008 (34)

10

Wang et al,
2010 (24)
Wang et al,
2009 (45)
Zhang et al,
2012 (59)

Dmean deviation from plan

COM displacement

nr

Weight loss

R2 0.55 (R),
0.39 (L)
R2 <0.4

Planned Dmean

PG vol loss

R 0.68

<0.001

15

Change in Dmean

Weight loss

<0.001

82

Dmean

PG vol loss at end of RT

R 0.81 (L)
R 0.89 (R)
R 0.404

11

Change in Dmean

Weight loss

Nil found

<0.001

Table 2.3. Studies reporting correlations with parotid gland dosimetry. R is the correlation coefficient and R2 is the squared correlation
coefficient.
N- number of patients, PG- parotid gland, incr- increase, decr- decrease, vol- volume, nr- not reported, ss- statistically significant, nsstatistically non-significant, D50- dose to 50 % of volume, Dmean- mean dose, ∆- difference of the parameter, ipsi- ipsilateral, contracontralateral, R- right, L- left, COM- centre of mass, BMI- body mass index, CTV70- Clinical Target Volume prescribed 70 Gy, PTV70Planning Target Volume prescribed 70 Gy, T- tumour, N-nodal.
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Study
Ahn et al,
2011 (18)

N
23

Spinal cord or
Brainstem endpoint
Dmax SpC incr

Need for replan due to
SpC Dmax overdose

Capelle et al,
2012 (27)

Castadot et al,
2011 (58)

20

10

Correlation parameter
Neck diameter decr at
mandibular joint
Neck diameter decr at
C4-6 vertebral level
Neck diameter decr at
mid-tumour level
Positional variations at
base of skull, mandible,
various levels of cervical
spine, lordosis

Correlation/
Association
R 0.30

P value
ss but nr

R 0.17-0.27
R 0.18
nr

significant p
values

Neck thickness change at
mid-PTV level
Neck thickness change at
thyroid notch level
GTV volume, weight
change, neck thickness at
C1 vertebra, T stage, N
stage

R 0.56

0.01

R 0.73

<0.0001

Difference between
planned + delivered SpC
D2
Difference between
delivered + ART SpC D2

Rate of GTV vol loss

R2 0.79

p= 0.0006

Rate of GTV vol loss

R2 0.75

p=0.001
nr

Dmax SpC

Nil found

Nishi et al,
2012 (33)

20

D2 SpC incr

GTVp vol loss

R 0.91

Qi et al, 2015
(26)

11

Dmax SpC

Weight loss

Nil found

Wang et al,
2010 (24)

15

Change in Dmax SpC
Change in Dmax BS

Weight loss
Weight loss

R 0.65
Nil found
36

<0.05

Zhang et al,
2012 (59)

11

D1 SpC, BS

Weight loss

Nil found

Table 2.4. Studies reporting correlations with spinal cord and brainstem dosimetry. R is the correlation coefficient and R2 is the squared
correlation coefficient.
N- number of patients, SpC- spinal cord, BS- brainstem, incr- increase, decr- decrease, vol- volume, D1- dose to 1 % of volume, D2- dose to
2 % of volume, Dmax- maximum dose, nr- not reported, ss- statistically significant, T- tumour, N- nodal.
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Study
Target
Volumes
Ahn et al,
2011 (18)

N

23

ROI endpoint

Correlation parameter

PTV nodal D95 incr

Neck diameter decr at
C1-5 vertebral level
PTV nodal vol decr
Neck diameter decr at
C1-3 level
PTV tumour + nodal vol
decr
Isocentre displacement
Positional variation at
base of skull
Weight loss
Positional variations at
base of skull, mandible,
various levels of cervical
spine

0.19-0.25

nr

0.099 (ns)
significant p
values

Weight change
Neck thickness change at
thyroid notch level
GTV volume, neck
thickness at C1 vertebra
and mid-PTV, T stage, N
stage
Weight change, GTV
volume, neck thickness
at C1 vertebra, mid-PTV
and thyroid notch, T
stage, N stage

R 0.59
R 0.51

0.01
0.02

Weight loss

Nil found

PTV tumour D95 incr

PTV underdose

PTV nodal underdose

Capelle et al,
2012 (27)

20

PTV low dose D1

PTV high dose D1

Qi et al, 2015
(26)

11

Mean dose PTV

38

Correlation/
Association

P value

ss but nr

0.27
0.23-0.24
0.30-0.31
nr

Nil found
Nil found

0.015
0.063 (ns)

Wang et al,
2010 (24)
Other OARs
Ahn et al,
2011 (18)

15

TV dosimetric endpoints

Weight loss

Nil found

23

Mandible V60 incr
Mandible overdose

GTV volume decr
Isocentre displacement
Positional variation at
Base of Skull, mandible
cochlea level

0.26
nr
nr

Vasquez
Osorio et al,
2008 (34)

10

Planned Dmean SMG

SMG vol loss

Nil found

Wang et al,
2009 (45)

82

Dmean SMG

Vol loss at end of RT

R 0.389

ss but nr
0.001-0.002
significant p
values

<0.001

Table 2.5. Studies reporting correlations with dosimetry of other structures. R is the correlation coefficient and R2 is the squared
correlation coefficient.
N- number of patients, ROI- Region of Interest, incr- increase, decr- decrease, D1- maximum dose to 1 % of volume, D95- dose to 95 % of
the volume, Dmean- mean dose, V60- volume receiving 60 Gy, TV- target volume, SMG- submandibular gland, T- tumour, N- nodal, volvolume, nr- not reported, ss- statistically significant, ns- statistically non-significant.
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2.8.3 Recommendations for ART Implementation
The previous sections of this chapter have built an argument for the routine use of ART in HNC
patients. However, there are numerous points to consider in the practical implementation of an
ART protocol; including:
i.

Resource availability

ii.

Identifying patients who would most benefit from ART

iii.

Identifying the best timing for ART

The impact on clinical resources has been discussed in section 2.8.1. Section 2.8.2 has explored how
patients may be identified for plan adaptation. Section 2.5 has highlighted how anatomical changes,
resulting in significant dosimetric alteration, have been identified early in the 35 fraction radiation
therapy course. Some investigators have made recommendations for implementing an ART
protocol, in terms of timing or selection criteria. These recommendations tend to mirror the
specific protocols employed by the investigators and are summarised in Table 2.6. However, it is
generally accepted that imaging and replanning early in the treatment course is beneficial.
Recommendations on the selection criteria for patients who may benefit is more variable.
Ahn et al (18) describe their approach to replanning their patients following a mid-course repeat
CT scan. An assessment of target volume and OAR dose coverage is made, but they also take into
account positional variations (based on daily CBCT imaging) as these have also been shown to
significantly impact dose delivery. Brouwer et al (48) conducted a review of the anatomic changes
and subsequent dosimetric consequences on OARs during HNC radiation therapy, to investigate
whether any criteria to select patients for ART may be identified. They conclude that, since
anatomical changes are more pronounced in the first half of treatment, the optimal timing for ART
should be within this time period. Potential criteria to select patients for ART, which they
recommend for further investigation in larger prospective trials, were tumour location
(nasopharyngeal carcinoma), age, Body Mass Index (BMI), planned parotid gland dose and initial
parotid gland volume. Brouwer et al (84), in a subsequent publication, propose a model for
selecting patients for ART, based on the planned mean parotid gland dose at planning, as discussed
in section 2.8.2

40

Study
Ahn et al,
2011 (18)

Selection criteria
Based on dose to TV + OAR and positional
variability

Timing
Mid-course imaging

Brouwer et al,
2015 (48)

Potential selection criteria for future
investigation

First half of treatment

Brouwer et al,
2016 (84)

PG Dmean >22.2 Gy at planning

Brown et al,
2015 (83)

High risk >80 % probability of replan
Intermediate risk 60-80 % probability of replan
Risk based on tumour location, nodal stage,
initial nodal size, initial weight

Castelli et al,
2016 (82)

Nomogram based on initial CTV dose, change in
PG Dmean and change in CTV dose at week 1

Cheng et al,
2012 (20)

At 30 Gy

Fiorentino et
al, 2012 (86)

Week 3

Huang et al,
2015 (25)

Fractions 5, 15

Zhang et al,
2016 (41)

3x during RT at week 1,2,5

Table 2.6. Studies reporting recommendations, in terms of selection criteria or optimal timing, for
implementing an ART protocol.
PG- parotid gland, Dmean- mean dose, CTV- Clinical Target Volume, RT- radiation therapy.

2.9 A Tool for Assessment of Patient Nutritional Status
This investigation will incorporate a nutritional tool; in the analysis of correlations between clinical
measures and inadequate IMRT plan dosimetry. The nutritional tool selected is the Patient
Generated Subjective Global Assessment (PG-SGA), which has been validated specifically in the
oncology population (16,17,87). It involves the assessment of patient weight, nutritional intake,
symptoms, patient functioning, metabolic stress and physical examination (Appendix 1). The
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dietician performing the assessment is then able to provide a global assessment of the nutritional
status (categories A, B, C), as well as a numerical score, which increases with worsening nutritional
status.
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Chapter 3
Methods
3.1 Study Design
The study design is a prospective single arm feasibility study. The study protocol attained local
Ethics Board approval.

3.2 Study Population
3.2.1 Patient Selection
Eligible patients were identified upon attendance at radiation oncology clinic consultation. Ten
participants were enrolled onto the study. Participants received information about the study
verbally, were provided with a written Patient Information Sheet and had the opportunity to ask
questions. All participants provided written informed consent and were aware that they could
withdraw their consent at any stage.

3.2.2 Eligibility Criteria
The following eligibility criteria were applied during patient selection.
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i.

Histologically or cytologically confirmed in situ primary mucosal head and neck squamous
cell carcinoma (HNSCC).

ii.

Treatment with primary radiotherapy with or without concurrent systemic therapy, with
curative intent, to a dose of 70 Gy.

iii.

Measurable disease on CT scan.

iv.

ECOG performance status 0 to 2 (Appendix 2).

v.

Age ≥18 years.

vi.

Able to comply with all treatment and assessments.

vii.

Ability to understand and willing to sign a written informed consent document.

3.2.3 Ineligibility Criteria
The presence of the following criteria resulted in ineligibility for study participation.
i.

Prior radiotherapy to the head and neck region.

ii.

Prior surgery to the head and neck region, apart from excision of basal cell carcinoma or
non-invasive squamous cell carcinoma of the skin.

iii.

Pregnant or lactating patients.

3.3 Pretreatment Evaluation
The following pretreatment evaluation was undertaken prior to study enrolment, and is
summarised in Table 3.1.
i.

Patient history for confirmation of eligibility and ineligibility criteria.

ii.

Physical examination of primary tumour and nodal regions, including flexible
nasoendoscopy.

iii.

Assessment of weight, ECOG performance status and nutritional score (PG-SGA).

iv.

Review of patient imaging; specifically the diagnostic CT scan, 18-Fluorodeoxyglucose
Positron Emission Tomography (FDG-PET) scan and Magnetic Resonance Imaging (MRI)
scan (if performed) to confirm the tumour site, laterality and tumour stage.

v.

Review and confirmation of patient histopathology.
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Required
Investigations
Clinical review
Medical History
Histopathology report
Physical examination
ECOG Performance
Status
Weight
PG-SGA score
Imaging
Diagnostic CT scan
PET scan
MRI scan
Conventional planning
CT scan

Prestudy

RT
planning

Fraction
5

Fraction
10

Fraction
15

Fraction
20

Fraction
25

Fraction
30

Fraction
35

✔
✔

✔
✔

✔
✔

✔
✔

✔
✔

✔
✔

✔
✔

✔
✔

✔

✔

✔

✔

✔

✔

✔

✔

✔
✔
✔
✔
✔
✔
✔
✔
optional

Table 3.1. Schedule of clinical patient review and imaging
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3.4 Radiation Treatment Planning and Plan Assessment
3.4.1 Radiation Treatment Schedule
Patients underwent IMRT five days a week for a total of thirty five fractions. At every fifth fraction,
commencing from fraction five and ending at fraction 35, a non-contrast conventional planning CT
scan was acquired (Table 3.1). In the case of four patients, an additional conventional planning CT
scan was acquired at fraction one, due to a protocol amendment. This was to investigate the
morphological changes which may have occurred between radiation treatment planning and the
start of treatment.
A flowchart summarising patient imaging and plan assessment is presented in Figure 3.1.

3.4.2 Planning CT Procedure
The patient was immobilised with a thermoplastic head and shoulder mask in the supine position,
to ensure adequate immobilisation during therapy and treatment reproducibility. A planning CT
scan using Siemens SOMATOM Sensation 16-slice scanner (SIEMENS, Erlangen, Germany) was
acquired with 2 mm axial slices and with the use of i.v. contrast. The CT scan extended from above
the vertex of the skull superiorly to below the suprasternal notch inferiorly. The isocentre was
placed at the inferior-anterior edge of the C4 vertebral body on mid-line.

3.4.3 Target Volume Definitions
All target volume and normal structure delineation was undertaken using the Pinnacle 3 Treatment
Planning System Versions 8.0m and 9.0 (Philips Medical Systems, Fitchburg, Wisconsin, USA) by the
chief investigator and checked by a second radiation oncologist. Volume of interest contours were
manually delineated using international consensus guidelines (88) and International Commission
on Radiation Units and Measurements (ICRU) report 62 definitions (89).
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Assessment of patient eligibility




Pre-treatment patient procedures
Planning CT scan with i.v. contrast
Dietician assessment

Manual delineation of contours

Radiation Treatment Planning &
Quality Assurance (QA) process

th




At every 5 fraction (†)
Non-contrast planning CT scan
Dietician assessment

Rigid registration with CT scan of
current radiation treatment plan

Manual delineation of contours

Treatment plan dose calculation on
newly acquired CT dataset

Is treatment plan on current CT dataset
acceptable?

Figure 3.1. Flowchart summarising patient imaging and plan assessment protocol. † Reimaging
commenced at fraction 5 for all patients except patients 6 to 9, who underwent an additional CT
scan at fraction 1 due to protocol amendment.
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Gross Tumour Volume was defined as visible tumour (labelled GTVp) and enlarged or suspicious
lymph nodes (labelled GTVn), identified clinically and radiographically with CT, FDG-PET and MRI
imaging. The Clinical Target Volume of the primary (CTVp) was defined by an expansion from the
GTVp, to anatomical boundaries of subclinical risk. The CTV of the involved lymph nodes (CTVn)
was a 3mm expansion of the GTVn into normal fat, with subsequent modification at anatomical
boundaries, e.g. skin, muscle and air cavity. The CTV of uninvolved nodal regions (CTVn0) was
delineated in the bilateral neck according to anatomical boundaries (e.g. air cavities, bones, fascial
planes) and excluded the CTVp and CTVn volumes. Intraobserver variability, when creating CTVs,
was minimized by recording the anatomical boundaries used when creating the target volumes,
facilitating their reproduction in following weeks. The Planning Target Volume was obtained by a
3mm expansion of the CTV, as per the institution IGRT protocol. Two PTVs were defined; PTV60
(low dose PTV), which was an expansion of the CTVp + CTVn + CTVn0; and PTV70 (high dose PTV),
which was an expansion of the CTVp + CTVn. Figures 3.2, 3.3 and 3.4 demonstrate the delineation of
tumour volumes in one representative patient.
Organ at Risk volumes were identified and contoured, including parotid and submandibular glands,
spinal canal, mandible and mucosa. The spinal canal and mandible were auto-delineated using CT
density threshold values. The mucosa was defined as a 2 mm annulus around the aerodigestive air
column. Some normal tissues (such as the lens, optic nerves, optic chiasm) were included when
considered at risk of exposure. Fat volumes were also auto-delineated using CT density thresholds.
The fat volumes were delineated for a maximum of nine slices around the isocentre slice.
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Figure 3.2. GTV and CTV delineation in a representative patient. Description of tumour volumes in
section 3.4.3. Red- GTVp, orange- CTVp, green- GTVn, light blue- CTVn, yellow- CTVn0
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Figure 3.3. Tumour volume delineation in a representative patient, demonstrating construction of
the PTV60. Description of tumour volumes in section 3.4.3. Red- GTVp, orange- CTVp, green- GTVn,
light blue- CTVn, yellow- CTVn0, blue- PTV60.
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Figure 3.4. Tumour volume delineation in a representative patient, demonstrating construction of
the PTV70. Description of tumour volumes in section 3.4.3. Red- GTVp, orange- CTVp, green- GTVn,
light blue- CTVn, purple- PTV70.
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3.4.4 Dose calculation
Dose calculation was performed using a collapsed cone convolution algorithm (90,91). This
calculation is based on a previously developed convolution method (92). The dose calculation grid
used was 2 mm x 2 mm x 2 mm.

3.4.5 Treatment Prescription
A total of 70 Gy (2 Gy/fraction) was prescribed to the PTV70; and 60 Gy (1.7 Gy/fraction) to the
PTV60 using seven-field inverse-planned IMRT (93) with simultaneous integrated boost technique
over 35 fractions. Treatment was delivered on Varian 21EX and 21iX linear accelerators, using step
and shoot delivery. 6 MV photon beams were selected. Treatment commenced within a median of
15 days (range 13-27) after planning CT. Daily IGRT using bone matched electronic portal imaging
(EPI) correction was performed as per departmental protocol at the time.

3.4.6 Weekly Imaging and IMRT Plan Assessment
All patients underwent a non-contrast planning CT scan every fifth fraction after commencement of
radiation therapy. Four patients also had an additional planning CT scan on day one of radiation
therapy, due to a protocol adjustment. At each CT scan, the fit of the immobilisation mask was
assessed by clinical inspection and additional bolus inserted or a new mask made if required. The
newly acquired CT dataset was aligned to the original CT scan using rigid registration. Deformable
Image Registration (DIR) software was not utilised in this investigation (as the technology was not
available in the department at the time of data collection), and all contour adjustment was done
manually.
For each CT scan, the tumour volumes (i.e. GTVs, CTVs and PTVs), parotid glands and spinal canal
were delineated by the chief investigator. The GTV was defined as the visible tumour (GTVp) and
enlarged lymph nodes (GTVn) as seen on the newly acquired CT scan. The CTVp was delineated
using the same principles as for the original planning CT scan; i.e. an expansion of the GTVp to the
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same anatomical boundaries which had been defined in the planning CT scan. This was in order to
reduce the risk of undertreating microscopic disease, which had been included in the original CTVp.
The CTVn remained a 3 mm expansion of the GTVn, with modification at anatomical boundaries, e.g.
skin, air cavity. The CTVn0 was generated according to the same anatomical boundaries defined for
the planning CT scan. The PTVs were a strictly geometric construct; i.e. a 3 mm expansion of the
relevant CTVs, as per the institutional IGRT protocol.
The original treatment plan was recalculated on the new CT dataset and plan acceptability was
assessed via pre-determined DVH parameters for PTV coverage and dose to spinal canal. An
unacceptable plan was defined as V95 <95 % for the PTV70 or PTV 60; or a spinal cord Dmax ≥ 45
Gy. The parotid gland dose was noted, but did not affect decision making. Unacceptable plans were
re-optimised and this adapted plan used for subsequent treatment and for subsequent weekly
comparison.
The volume of the contoured structures (GTVs, CTVs, PTVs, parotid and submandibular glands) on
the weekly CT imaging was recorded. The volume of subcutaneous fat was recorded, across a
maximum of nine slices with the isocentre slice at the centre. Image registration was used to collate
all of the parotid gland contours onto a single scan. Parotid gland movement was calculated by
measuring the shift of the centre of mass (COM) coordinates relative to the original planning CT
scan. It was acknowledged that any uncertainty in image registration would impact on the results of
the contour comparison as image registration was used to collate all of the contours onto a single
scan, however this method has been used in other investigations (94). The lateral border position of
the parotid glands was calculated as half the width of the gland in the lateral direction from the
COM point. Some submandibular glands were delineated retrospectively and therefore all contours
were not collated onto a single scan. The submandibular gland movement was calculated by
measuring the shift of the COM coordinates relative to the isocentre coordinates. This method is not
as robust as the method used to calculate parotid gland shift.

3.4.7 Weekly Patient Assessment
Patients underwent assessment on the day of their initial planning CT scan and each time they
underwent a repeat planning CT scan (Table 3.1). Weight was measured without shoes, with a
similar amount of clothing and before chemotherapy if possible. A Patient Generated Subjective
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Global Assessment (PG-SGA) was performed by a registered dietician (Appendix 1), in order to
document the patient nutritional status.

3.4.8 Statistical Analysis
Graphpad Prism 6 for Windows (Version 6.05, La Jolla, CA, USA) and IBM SPSS software version 20
(SPSS, Chicago, IL, USA) were used for statistical analysis. Sample t-tests were used to assess
volumetric and geometric changes in target volumes and OARs, as well as dosimetric changes in the
unadapted IMRT plans. Comparisons between the original and adaptive plans were performed
using two-sided paired t-tests. A probability value < 0.05 was considered significant. Correlation
between patient nutritional score and weight versus PTV70 coverage over the treatment was
investigated using Pearson’s correlation, since the Shapiro-Wilk test demonstrated that the data
exhibited a normal distribution.

3.4.9 Comparison of Methodology with Other Studies
This investigation involves dosimetric evaluation of oncologist-defined structures on planning CT
scans at every fifth fraction, therefore allowing regular assessment of the “actual” dose delivery as
anatomical changes occur.Therefore a truly adaptive approach is implemented; as patients are
treated with a re-optimised plan when dose delivery is assessed as suboptimal, within 24 to 48
hours of the new planning CT scan. A subopimal dose delivery was defined using DVH assessment
parameters, as described in section 3.4.5.
Other published studies have reported an ART approach, whereby patients were treated with a reoptimised plan during the course of radiation treatment for HNSCC. The frequency of re-imaging
varies in these studies, with only two studies describing a weekly dose calculation protocol.
In the study published by Schwartz et al (23), 24 patients underwent daily in-room CT scanning
with weekly dose calculation and IMRT plan recalculation on contours generated using a
deformable-image registration technique. However, in this current investigation, all contours are
manually defined. The frequency of dosimetric evaluation by Schwartz et al is the same as in this
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current investigation,however additional IMRT recalculation was performed if significant
discepancies were found between the contour overlay on the daily CT scans and the treatment
planning scan.
Jensen et al (52) also report their protocol of weekly CT imaging. IMRT plan reoptimisation was
only undertaken if there was >1 cm discrepancy between the target volume (specifically the CTV)
or OAR contours on the newly aquired CT images and the original TV or OAR contours. In other
words, a decision to replan was based on an assessment of differences in contour overlay, rather
than a dosimetric evaluation. Dosimetric assessment was subsequently performed retrospectively,
but only on those patients who underwent a plan reoptimisation. Therefore, the question of
whether assessment of contour overlay was an adequate alternative to prospectively performed
dosimetric evaluation was not addressed in their study.
The study by Ahn et al (18), describes imaging at three time points during the treatment course, at
fractions 11, 22 and 33. Patients underwent replanning if there was inadequate target volume
coverage (defined for the GTV, CTV and PTV structures) or if OAR constraints were not met. Wang
et al (76), describe their protocol of a single re-imaging at fraction 25 in patients with
nasopharyngeal tumours. All patients underwent IMRT plan recalculation and subsequent
treatment with the reoptimised plan, regardless of TV and OAR coverage. Finally, the protocol
described by Cheng et al (20) involves CT and MRI imaging at fractions 15 and 25 in patients
treated for nasopharyngeal tumours. IMRT plan reoptimisation was undertaken if OAR doses
exceeded their tolerance doses or if target volume coverage was deemed unsatisfactory by the
treating oncologist (these values are not defined in the paper).
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CHAPTER 4
General Results
4.1 Patient Cohort
Of the ten enrolled patients, nine were male. The mean age of the patient cohort was 63.7 years
(range 49-82y).
Patient characteristics are summarised in Table 4.1. Eight of ten patients had a diagnosis of
oropharyngeal SCC; the remaining two patients had a diagnosis of nasopharyngeal and
hypopharyngeal SCC. Two patients had early stage node-negative (T1N0) oropharyngeal SCC, and
did not receive concurrent systemic therapy. Of the eight patients receiving concurrent systemic
therapy, six were treated with weekly Cisplatin, and one was treated with weekly Cetuximab.
Patient 6 was switched from Cisplatin to Cetuximab systemic therapy in the third week of
radiotherapy due to the development of ototoxicity. Table 4.2 summarises the clinical outcomes of
the patients; four patients remain alive and cancer–free.

4.2 Adaptive Replanning
A total of 84 CT scans were analysed. Six patients had a total of eight scans; the remaining four
patients (Patients 6 to 9) had a total of nine scans. This was due to a protocol amendment (as
described in section 3.4.1) to include a CT scan obtained at fraction 1. A total of 22 plan adaptations
were required.
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All plan adaptation events were triggered due to inadequate PTV coverage, rather than
unacceptable spinal cord dose. As described in section 3.4.5, parotid gland dose parameters were
not used to trigger plan adaptation.

Patient
number

Site

TNM
stage

Concurrent
Chemotherapy

1

Oropharynx

T3N1M0 Cisplatin

Total
number of
plan
adaptations
1

2

Nasopharynx

T4N2M0 Cisplatin

2

10,20

3

Hypopharynx T3N2M0 Cisplatin

1

10

4

Oropharynx

T1N0M0 Nil

0

5

Oropharynx

T4N2M0 Cisplatin

3

5,10,25

6

Oropharynx

T2N2M0 Cisplatin/Cetuximab

5

1,5,15,20,30

7

Oropharynx

T2N2M0 Cetuximab

3

15,25,30

8

Oropharynx

T3N2M0 Cisplatin

3

1,5,30

9

Oropharynx

T1N0M0 Nil

0

10

Oropharynx

T3N2M0 Cisplatin

4

Table 4.1. Main patient characteristics and adaptive planning schedule.
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Adaptive plan
timings (fraction
number)
10

15,20,25,30

Recurrence

Duration of
Survival
(yrs)
1.88

Time to
Recurrence
(yrs)

1.32

0.52

Patient
number

Alive (A) or
Deceased (D)

Cause of
Death

1

D

O

2

D

C

3

D

O*

2.25

4

D

O

2.70

5

A

8.62

6

A

7.84

7

A

7.25

8

D

9

A

10

D

DR

C

DR

0.98

0.34

6.52
C

LR

0.72

0.00

Table 4.2. Patient survival outcomes.
C- Cancer, O- Other cause, LR- Local Recurrence, RR- Regional Recurrence, DR- Distant Recurrence.
*- deceased due to a different cancer
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4.2.1 Plan Adaptation Timing and Frequency
The timing of adaptive replanning in each patient is shown in Table 4.1. Two patients (patients 4
and 9) required no treatment plan adaptation during the course of radiotherapy; both had a
diagnosis of early stage node-negative oropharyngeal SCC.
Of the four patients (patients 6 to 9) that underwent an additional CT scan at fraction one, two of
them (patients 6 and 8), required adaptation of their treatment plan at fraction one, due to
significant anatomical change resulting in unacceptable dose delivery to the PTV. The number of
days between planning CT and fraction one of treatment was 20 days for patient 6 and 13 days for
patient 8. By contrast, the delay between the planning CT scan and fraction one was 14 days for
patient 7 and 27 days for patient 9. Despite a longer than usual delay for patient 9, the fact that they
had early stage node-negative disease probably explains why plan adaptation was not triggered at
fraction one.
The mean number of plan adaptations for the patient cohort was two (range 0-5). Figure 4.1 and
Table 4.3 demonstrate the timing of plan adaptations throughout the treatment course. Nine (41 %)
plan adaptations were required at or before fraction 10; whilst 12 (55 %) of the total 22 plan
adaptations occurred by fraction 15. All first plan adaptations and half of the second plan
adaptations had occurred by fraction 15. Four patients also underwent plan adaptations at fraction
30, just days before the end of a 35 fraction course of radiation therapy.
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Figure 4.1. Timing of adaptive replanning, for first, second and subsequent plan adaptations
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Fraction
number

Number of
plan
adaptations

Cumulative
percentage of total
plan adaptations
(%)

2

Percentage
of total
plan
adaptations
(%)
9.1

1
5

3

13.6

22.7

10

4

18.2

40.9

15

3

13.6

54.5

20

3

13.6

68.2

25

3

13.6

81.8

30

4

18.2

100.0

Total

22

99.9

9.1

Table 4.3. Frequency of weekly plan adaptations

4.3 Weight and Nutritional Score
4.3.1 Weight Loss and the Need for New Bolus or Immobilisation Mask
The weekly mean weight change for the patient cohort is shown in Figure 4.2. The mean weight loss
during treatment for all patients was 5.6 kg (range 0.3 to 10.0kg).
Two patients (patients 2 and 6) required the making of new immobilisation masks; both at fraction
20, due to a clinical evaluation revealing the existing mask to be too loose. Both of these patients
also required adaptive replanning at this stage, due to unacceptable dose to PTV. The weight loss of
these two patients at fraction 20 was 6.2 kg and 6.8 kg; double the mean weight loss of 3.1 kg
(range +0.8 kg to -6.8 kg) of all ten patients at this time.
Three patients (patients 6, 7, 10) required the addition of bolus material to fill air gaps between the
immobilisation mask and skin. The gaps were not considered large enough to require a new
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immobilisation mask. In all instances, the addition of bolus material was also accompanied by an
adaptive replanning event, due to unacceptable PTV dose. For patient 6, new bolus material was
added at fraction 15. Patient 6 subsequently had a new immobilisation mask made five fractions
later as described above. Patient 7 had new bolus material added at fractions 15 and 25; patient 10
received additional bolus material at fraction 25.

Figure 1: Patient weight loss and PGSGA score
20

8
7

15

6
5

10

4
3

5

2

Mean weight loss (kg)

1

Mean PGSGA score

0

Pl

1

5

10

15

20

25

30

35

40

0

Fraction number
Figure 4.2. Mean patient weight loss and PGSGA score during treatment
Pl- on RT planning day

4.3.2 Change in Nutritional Score
Nutritional status was measured using the PG-SGA assessment as described in section 3.4.6. The
mean PG-SGA score increased during the treatment period (Figure 4.2), indicating worsening
nutritional status. The weekly mean PG-SGA score and PG-SGA category is shown in Table 4.4. At
the time of radiotherapy planning, the mean PG-SGA score was 5 (range 1-11) compared to a score
of 17 (range 11-28) at fraction 35. There are three PG-SGA categories (A, B, C); where A is the best
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nutritional category and C the worst. There was also deterioration in PG-SGA category between
planning and at fraction 35. At the time of radiotherapy planning, all patients scored in Category A.
At fraction 35, most patients were now in category B.

Fraction
number

Mean PGSGA score

Number of patients in each PG-SGA
category
Cat A
Cat B
Cat C
10
0
0

Planning

5

5

9

7

3

0

10

11

5

5

0

15

15

2

8

0

20

16

1

9

0

25

15

2

8

0

30

16

1

9

0

35*

17

1

7

1

Table 4.4. Mean PG-SGA score and PG-SGA category frequency for the patient cohort.
*- missing data from patient 10.

4.4 Correlation with Plan Adaptation Requirement
There was no correlation found between the change in weight and the change in PTV70 coverage;
correlation coefficient -0.135 (p=0.256). Similarly, there was no correlation found between the
change in patient PG-SGA score and change in PTV70 coverage; correlation coefficient -0.046
(p=0.703).
There was a significant correlation found between change in weight and change in PG-SGA score;
correlation coefficient 0.909 (p=0.002). This correlation can be seen in Figure 4.2, where the lines
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of patient weight loss and PG-SGA score are practically parallel. This correlation is not completely
surprising, as the PG-SGA score is derived from a number of factors, one of which is weight.
In addition, it was found that larger initial nodal volumes correlated with a higher number of plan
adaptations required throughout the treatment course, as shown in Figure 4.3. The Pearson’s
correlation coefficient was 0.708 (p=0.022).

Figure 4.3. Patient initial nodal volume vs. total number of plan adaptations required

4.5 Overall Time for Target Delineation and Planning Processes
It took approximately one hour for CT scan acquisition, rigid registration and dose recalculation.
The subsequent delineation of contours took a median time of 240 minutes (range 210-270) for the
original planning CT scan, and 180 minutes (range 80-270) for subsequent scans. The
reoptimisation of treatment plan, dosimetry and Quality Assurance procedures were not measured
for this investigation, but took approximately one working day to complete.
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Chapter 5
Anatomical Changes Observed during H+N
IMRT
5.1 Volumetric Changes in Target Volumes
As described in Section 3.4.3, the GTVp, GTVn, CTVp, CTVn and CTVn0 were delineated manually.
The PTV70 and PTV60 were created as an expansion of the relevant CTV volumes.

5.1.1 Full Patient Cohort
All Target Volumes, with the exception of the CTVn0 and PTV60 exhibited volume reduction over
the treatment period, with significant reduction by fraction 35. The mean weekly volumes of these
target volumes is summarised in Table 5.1. The GTVp reduced in volume from fraction 10, whereas
a significant volume reduction in GTVn was not demonstrated till fraction 20. By fraction 35, the
mean volume reduction was 25 % for the GTVp, 44 % for GTVn, 18 % for CTVp, 28 % for CTVn and
11 % for the PTV70.
The CTVn0 and PTV60 did not demonstrate significant volume change, which reflects the method
by which the CTVn0 is delineated. The CTVn0 is the “non-muscle, non-bone” soft tissue space where
at-risk, but non-visible, lymph nodes are situated. Logically, this soft tissue space would not be
expected to reduce in volume as much as target volumes that are based on the presence of visible
tumour (i.e. the CTVp and CTVn). The CTVn0 forms the majority volume of PTV60 construct; the
other smaller components being the CTVp and CTVn. Therefore, it is reasonable that the PTV60
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would not demonstrate significant volume reduction by fraction 35 given the relatively stable
volume of the CTVn0.

5.1.2 Patients with CT Scan at Fraction One
Due to a protocol amendment, four of the ten patients underwent an additional CT scan at fraction
one. The volumetric change of the TVs between planning CT and fraction one is shown in Table 5.2.
There was an increase in tumour volume (GTVp and GTVn) between planning CT and fraction one;
the GTVn increased more than the GTVp. Patients 6 and 8 required plan adaptations at fraction one.
A larger increase in PTV70 and PTV60 volumes was observed in these patients, compared to the
two patients who did not require plan adaptation. It would seem reasonable that, with a greater
volume increase in the PTVs, the initial isodose distributions would not cover the subsequently
larger PTVs at fraction one; therefore necessitating a plan adaptation at this stage.
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GTVp
GTVn
CTVp
CTVn
CTVn0
PTV70
PTV60
Fraction volume (ml);
P
volume (ml);
P
volume (ml);
P
volume (ml);
P
volume (ml);
P
volume (ml);
P
volume (ml);
P
number
Volume
value
Volume
value
Volume
value
Volume
value
Volume
value
Volume
value
Volume
value
change (%)
change (%)
change (%)
change (%)
change (%)
change (%)
change (%)
Planning
5
10
15
20
25
30
35

21.5 ±15.0
22.0 ±16.0;
1.7 ±5.6
20.1 ±15.4;
-10.3 ±10.9
18.5 ±15.1;
-17.1 ±18.6
18.2 ±14.8;
-21.1 ±17.8
17.9 ±14.9;
-22.8 ±20.6
17.0 ±13.6;
-26.0 ±19.4
18.7 ±14.9;
-24.6 ±22.9

16.4 ±9.9
0.38
0.02
0.05
<0.01
<0.01
<0.01
<0.01

16.2 ±11.6;
-3.5 ±28.6
14.2 ±9.1;
-6.5 ±33.2
13.2 ±9.3;
-10.9 ±43.3
11.1 ±7.9;
-24.7 ±39.9
9.9 ±7.4;
-32.9 ±35.9
9.4 ±7.1;
-37.0 ±31.7
9.1 ±7.6;
-44.3 ±25.0

51.2 ±29.5
0.89
0.14
0.09
0.03
0.02
0.02
0.03

51.8 ±27.6;
3.9 ±14.7
47.9 ±27.1;
-5.0 ±12.9
47.3 ±29.9;
-7.8 ±16.3
45.4 ±26.1;
-10.6 ±12.7
46.5 ±27.7;
-8.3 ±15.4
47.6 ±28.4;
-6.4 ±18.1
47.1 ±30.4;
-18.0 ±32.1

48.4 ±22.7
0.69
0.07
0.07
0.01
0.09
0.14
0.05

48.5 ±25.4;
2.9 ±27.7
45.4 ±20.7;
-2.6 ±18.9
43.7 ±21.4;
-7.4 ±17.1
38.7 ±19.0;
-15.6 ±26.1
37.1 ±19.4;
-21.5 ±20.4
36.0 ±19.3;
-24.7 ±20.0
35.5 ±19.6;
-28.1 ±19.8

171.7 ±51.7
0.97
0.19
0.10
0.03
0.02
0.02
0.03

168.7 ±49.4;
-1.2 ±5.7
173.6 ±48.6;
2.2 ±10.2
168.5 ±57.0;
-2.3 ±6.3
167.3 ±52.4;
-2.1 ±7.9
166.3 ±51.1;
-2.5 ±8.3
164.8 ±49.9;
-3.2 ±9.8
162.9 ±54.1;
-2.0 ±9.5

162.7 ±81.1
0.33
0.72
0.43
0.37
0.31
0.22
0.44

166.8 ±84.3;
2.5 ±10.7
157.6 ±78.2;
3.6 ±7.0
152.6 ±77.7;
-7.1 ±8.6
145.9 ±74.0;
-10.2 ±12.0
148.1 ±77.2;
-8.5 ±11.7
147.4 ±76.4;
-8.6 ±15.2
143.8 ±77.7;
-10.9 ±12.8

480.6 ±109.6
0.49
0.18
0.03
0.02
0.03
0.06
0.04

485.1 ±100.0;
1.4 ±4.5
476.7 ±100.5;
-0.4 ±4.7
471.2 ±113.4;
-2.0 ±5.8
465.5 ±93.6;
-2.5 ±6.0
466.4 ±99.0;
-2.4 ±6.5
464.9 ±103.2;
-2.9 ±5.9
459.3 ±108.2;
-2.6 ±5.8

Table 5.1. Mean volume (+ standard deviation) of target volumes during radiation treatment. Volume changes measured against the
planning volume.
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0.51
0.56
0.33
0.15
0.19
0.11
0.17

Target
Volume

GTVp

GTVn

CTVp

CTVn

CTVn0

PTV70

PTV60

Volume at

Volume at

Volume

Volume

Planning

Fraction 0

change

change

(ml)

(ml)

(ml)

(%)

#6

11.85

12.41

0.6

4.7

#7

18.06

18.29

0.2

1.3

#8

13.36

14.36

1.0

7.5

#9

8.60

8.94

0.3

4.0

#6

18.05

22.79

4.7

26.3

#7

28.17

29.56

1.4

4.9

#8
#9

22.67
0

24.07
0

1.4
-

6.2
-

#6

24.81

32.33

7.5

30.3

#7

53.64

49.69

-4.0

-7.4

#8

28.53

30.47

1.9

6.8

#9

26.41

25.66

-0.8

-2.8

#6

50.21

60.57

10.4

20.6

#7

75.06

79.70

4.6

6.2

#8
#9

52.17
0

56.94
0

4.8
-

9.1
-

#6

137.00

126.35

-10.7

-7.8

#7

112.36

113.93

1.6

1.4

#8

102.93

103.99

1.1

1.0

#9

153.97

145.33

-8.6

-5.6

#6

155.09

183.40

28.3

18.3

#7

237.82

239.29

1.5

0.6

#8

153.77

168.89

15.1

9.8

#9

55.88

54.34

-1.5

-2.8

#6

416.41

450.81

34.4

8.3

#7

474.27

483.48

9.2

1.9

#8

367.65

388.34

20.7

5.6

#9

376.03

365.67

-10.4

-2.8

Patient

Table 5.2. Volume changes in TVs of patients who underwent CT imaging at fraction one.
Patient 9 had no suspicious or enlarged LN, therefore does not have the GTVn or CTVn
defined.
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5.2 Volumetric Changes in Salivary Glands
5.2.1 Parotid Glands
The parotid glands demonstrated a reduction in volume from the start of treatment,
with a significant volume loss demonstrated commencing at fraction five. Mean parotid
gland volume change is demonstrated in Table 5.3. At fraction 35, the mean parotid
gland volume had significantly reduced by 7.09 ml (range 0.82 – 17.44 ml) or 28.0 %
(range 4.3 – 45.3 %, p <0.01). This translates to a volume reduction of 0.20 ml or 0.8 %
per day.

5.2.2 Submandibular Glands
The submandibular glands demonstrated a reduction in volume from the start of
treatment. As with the parotid glands, a significant volume loss was demonstrated
commencing at fraction five. Mean submandibular gland volume change is
demonstrated in Table 5.4. Mean submandibular gland volume reduction was 2.10 ml
(range 0.30 – 4.05 ml) or 25.7 % (range 3.1 – 46.4 %, p <0.01) at fraction 35. This
translates to a volume reduction of 0.06 ml or 0.7 % per day, which is similar to the
magnitude of parotid gland volume loss.
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Fraction
Mean volume
(ml)
Standard
deviation (ml)
Volume
reduction (ml)
Volume
reduction (%)
Weekly
reduction (%)
p value

Planning

5

10

15

20

25

30

35

25.29

24.03

23.03

21.57

20.64

19.33

18.66

18.20

6.16

5.60

5.27

4.63

4.59

4.49

3.78

4.13

1.26

2.26

3.73

4.65

5.97

6.64

7.09

4.98

8.94

14.75

18.39

23.61

26.26

28.0

4.98

3.96

5.81

3.64

5.22

2.65

1.74

0.02

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

Table 5.3. Mean Parotid Gland (right and left) volume, with standard deviation, during the treatment period. Volume reduction is compared to planning
volume.
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Fraction

Planning

5

10

15

20

25

30

35

Mean volume
(ml)
Standard
deviation (ml)
Volume
reduction (ml)
Volume
reduction (%)
Weekly
reduction (%)
p value

8.16

7.67

7.18

6.65

6.29

6.01

5.95

6.06

1.54

1.49

1.51

1.38

1.46

1.65

1.63

1.78

0.48

0.98

1.50

1.87

2.14

2.21

2.10

5.88

12.01

18.38

22.92

26.23

27.08

25.73

5.88

6.13

6.37

4.54

3.31

0.85

-1.35

0.02

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

Table 5.4. Mean Submandibular Gland (right and left) volume, with standard deviation, during the treatment period. Volume reduction is compared to
planning volume.
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5.3 Positional Changes in Salivary Glands
5.3.1 Parotid Gland
Table 5.5 demonstrates the movement of the parotid glands over the IMRT course. The
movement of the whole parotid gland was measured using two different methods.
Firstly, the relative shift of the COM of the gland relative to the COM position on the
planning CT scan was measured in the x, y and z planes. The second method calculated
the distance between the COM of the right and left parotid glands in the medial/lateral
plane and then determined whether this distance changed relative to the distance on the
planning CT scan. A smaller distance would indicate that the parotid glands had shifted
medially and were therefore closer together. Neither of these methods demonstrated
any significant displacement of the parotid gland relative to the planning CT scan.
The relative movement of the lateral border of the parotid gland was also measured, by
calculating the distance between the lateral border and the COM of the parotid gland
(Table 5.5). The lateral border of the parotid glands demonstrated a significant medial
shift at fractions 30 and 35. At fraction 35, there was a medial shift of 1.2 mm (range -0.1
to 3.4 mm; p=0.02); although the centres of mass of the whole parotid gland did not shift
medially (p=0.65).
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Centre Of
Mass
change

Change in
mediallateral
distance
between R
and L
Centre Of
Mass

Change in
position of
lateral
edge

p
value

Planning
5
10
15
20
25
30
35

Mediallateral
shift
(mm) #
0.0
-0.2
-0.1
-0.5
0.2
-0.1
0.2
-0.3

p
value

Planning
5
10
15
20
25
30
35

Change
in
distance
(mm) @
0.0
1.9
1.3
1.0
-0.3
0.2
-0.5
0.4

p
value

Planning
5
10
15
20
25
30
35

Change
in
distance
(mm) @
0.0
-0.2
0.2
0.4
0.8
0.7
1.1
1.2

0.55
0.65
0.21
0.72
0.84
0.64
0.65

Anteriorposterior
shift
(mm) $
0.0
-0.2
0.6
0.3
0.3
0.0
0.1
-0.2

p
value

0.70
0.30
0.36
0.61
0.92
0.83
0.81

Superiorinferior
shift
(mm) ^
0.0
0.1
-0.2
-0.2
0.0
-0.1
0.0
0.0

p
value

0.83
0.78
0.77
0.97
0.83
0.94
0.98

0.50
0.63
0.27
0.75
0.88
0.66
0.41

0.69
0.58
0.39
0.13
0.16
0.03
0.02

Table 5.5. Parotid Gland movement, relative to position at planning CT scan, measured
by different calculation methods. # positive value denotes a medial shift; $ positive value
denotes an anterior shift; ^ positive value denotes an inferior shift. @ positive value
denotes increased distance between the two points.
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5.3.2 Submandibular Gland
The movement of the whole submandibular gland was measured by calculating the
relative shift of the COM of the gland relative to the COM position on the planning CT
scan in the x, y and z planes. There was no significant shift of gland in the medial-lateral
or anterior-posterior planes. However, a significant superior shift of the submandibular
gland was observed at all fractions, except at fractions 20 and 35. At fraction 30, a 2.4
mm superior shift (range -2.3 to 10.3 mm, p=0.02) was observed (Table 5.6).

Fraction
number
Centre Of
Mass
change

Planning
5
10
15
20
25
30
35

Mediallateral
shift
(mm) #
0.0
0.4
0.1
-0.2
0.1
0.2
0.9
-0.3

p
value

0.44
0.93
0.86
0.94
0.83
0.39
0.74

Anteriorposterior
shift
(mm) $
0.0
-0.5
-0.8
0.5
0.5
0.8
1.5
-1.3

p
value

0.44
0.60
0.01
0.96
0.51
0.17
0.07

Superiorinferior
shift
(mm) ^
0.0
-1.6
-1.5
-1.7
-1.7
-2.6
-2.4
-1.3

p
value

0.036
0.049
<0.01
0.058
<0.01
0.021
0.206

Table 5.6. Submandibular Gland movement, relative to position at planning CT scan. #
positive value denotes a medial shift; $ positive value denotes an anterior shift; ^
positive value denotes an inferior shift.

5.4 Volumetric Changes in Subcutaneous Fat
The volume of fat was calculated on a single CT scan slice (at the isocentre level), as well
as over larger number of slices (3, 5, 7 and 9) centred around the isocentre slice. There
was a significant loss of fat volume seen in fractions 20, 25 and 35, only when measuring
fat volume on a single CT scan slice (Table 5.7). By fraction 35, the volume of fat loss was
1.9 mL or 24.9 % compared to the volume on the planning CT scan (Table 5.8). However,
this result was not replicated when calculating fat volume on greater numbers of slices.
Volume reductions were still observed, ranging from 12 and 13 %; but these results
were not statistically significant. As the single isocentre slice is less likely to be
representative of the entire fat volume, than when calculating on multiple CT scan slices,
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the fat volume loss noted on a single CT scan slice is probably not a true representation
of true fat volume changes.
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Fraction
1 slice fat
3 slice fat
5 slice fat
7 slice fat
9 slice fat
P value
P value
P value
P value
P value
number volume (ml)
volume (ml)
volume (ml)
volume (ml)
volume (ml)
Planning

7.7 ±3.8

29.2 ±14.3

48.8 ±23.6

68.3 ±32.4

87.9 ±40.9

5

7.6 ±3.4

0.61

29.4 ±13.0

0.78

48.8 ±21.5

0.96

68.3 ±29.7

0.98

87.7 ±37.8

0.93

10

7.1 ±3.3

0.12

28.0 ±12.2

0.26

47.0 ±20.2

0.29

66.3 ±28.0

0.35

85.9 ±35.9

0.42

15

7.0 ±3.4

0.21

28.6 ±12.5

0.64

47.6 ±20.7

0.55

66.7 ±28.7

0.52

86.2 ±37.1

0.56

20

6.6 ±3.2

0.11

27.8 ±12.3

0.35

46.4 ±20.4

0.31

65.1 ±28.3

0.29

83.7 ±35.8

0.26

25

6.7 ±3.0

0.04

26.9 ±10.5

0.19

45.0 ±17.4

0.18

63.2 ±24.2

0.17

81.4 ±30.9

0.16

30

6.0 ±2.5

0.01

26.6 ±9.7

0.07

44.5 ±16.4

0.06

62.4 ±23.0

0.06

80.4 ±29.9

0.05

35

5.8 ±2.8

0.03

25.4 ±11.3

0.11

42.5 ±18.9

0.10

59.8 ±26.4

0.09

77.3 ±34.1

0.09

Table 5.7 Mean volume (+ standard deviation) of fat during radiation treatment; measuring fat volume in different numbers of CT scan slices.
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Reduction in volume
between planning and
fraction 35
Volume
Percentage
(mL)
(%)
1 slice fat
volume (ml)
3 slice fat
volume (ml)
5 slice fat
volume (ml)
7 slice fat
volume (ml)
9 slice fat
volume (ml)

P value

1.9

24.9

0.03

3.8

12.9

NS

6.3

12.9

NS

8.5

12.5

NS

10.7

12.1

NS

Table 5.8. Mean reduction in volume of fat during radiation treatment; measuring fat
volume in different numbers of CT scan slices. NS- Non significant result.
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Chapter 6
Dosimetric Changes Observed during
H+N IMRT
6.1 Dosimetric Changes in Planning Target Volumes
6.1.1 Original IMRT Plan
There was a significant reduction in dose to both the PTV70 and PTV60 with the original
IMRT plan, as shown in Figure 6.1. The reduction in dose to the PTV structures became
significant from fraction five (Table 6.1). The mean V95 was less than 95 % for the
PTV70 from fraction five onwards; and for the PTV60 from fraction 20 onwards. The
results for fraction one were non-significant; however these data derive from only four
patients (hence the wider 95 % confidence intervals) and therefore these data should be
interpreted with caution.
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Figure 6.1. Mean V95 coverage, with 95 % confidence intervals, of PTV70 and PTV60 for the original IMRT plan on weekly
anatomy. Four patients only had data for fraction one. Pl- at RT planning.
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Fraction number

Mean V95 value
Mean V95 value
P value
P value
of PTV70 (%)
of PTV60 (%)

Planning

97.4 ±2.0

98.0 ±1.0

1

94.1 ±4.6

0.13

95.7 ±2.6

0.10

5

93.2 ±4.8

0.02

96.2 ±2.1

<0.01

10

91.9 ±4.7

<0.01

96.0 ±2.3

<0.01

15

90.4 ±6.9

<0.01

95.5 ±3.0

0.01

20

89.8 ±8.9

0.02

94.0 ±3.9

0.01

25

88.6 ±8.3

<0.01

93.9 ±3.1

<0.01

30

87.8 ±11.6

0.02

94.0 ±3.8

0.01

35

90.6 ±8.4

0.03

94.1 ±3.2

<0.01

Table 6.1. Mean PTV coverage (+ standard deviation) of the Planning Target Volumes
(PTV70 and PTV60) with original IMRT plan. Four patients only had data for fraction
one.

6.1.2 IMRT Plan Adaptation
IMRT plan adaptation significantly improved both PTV70 coverage (overall p value of
0.0004) and PTV 60 coverage (overall p value of 0.0012), as shown in Figure 6.2. Table
6.2 demonstrates the weekly PTV70 and PTV60 coverage for the original treatment plan
on the weekly anatomy (as if no plan optimisation was performed throughout the whole
treatment) and for the adaptive planning strategy (one or more IMRT plan
optimisations) in the patient cohort. When calculated weekly, the significant
improvement with ART was seen for fractions 10 to 30 for the PTV70; and fractions 20
to 35 for the PTV60.
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Fraction
number

Mean V95 value of
PTV70 (%)
Original
Adaptive
IMRT plan strategy

P value

Mean V95 value of
PTV60 (%)
Original Adaptive
IMRT
strategy
plan
98.0 ±1.0

P value

Planning

97.4 ±2.0

1

94.1 ±4.6

97.8 ±0.5

0.164

95.7 ±2.6

97.4 ±1.1

0.264

5

93.2 ±4.8

95.6 ±4.5

0.256

96.2 ±2.1

97.0 ±2.1

0.404

10

91.9 ±4.7

97.1 ±3.0

0.009

96.0 ±2.3

97.6 ±1.1

0.061

15

90.4 ±6.9

96.9 ±1.9

0.009

95.5 ±3.0

97.2 ±1.0

0.100

20

89.8 ±8.9

96.2 ±3.5

0.048

94.0 ±3.9

97.5 ±1.5

0.019

25

88.6 ±8.3

95.3 ±4.3

0.036

93.9 ±3.1

97.3 ±1.4

0.005

30

87.8 ±11.6

95.9 ±4.3

0.055

94.0 ±3.8

97.9 ±1.2

0.006

35

90.6 ±8.4

95.3 ±5.7

0.184

94.1 ±3.2

97.5 ±1.4

0.010

Table 6.2. Mean PTV coverage (+ standard deviation) of original plan versus adaptive
planning strategy during radiation treatment. Four patients only had data for fraction
one.
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Figure 6.2. Mean V95 coverage, with 95 % confidence intervals of (a) PTV70 and (b)
PTV60, for the original treatment plan on weekly anatomy vs. adaptive planning
strategy. Four patients only had data for fraction one.
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6.2 Dosimetric Changes in Parotid Glands
6.2.1 Original IMRT Plan
The parotid gland dose is measured in terms of V26 for this investigation; i.e. the volume
of the gland (in percentage value) receiving >26 Gy. There was a significant reduction in
mean dose to the parotid glands with the original IMRT plan, with the exception of
fractions one and 20 (Table 6.3). The data for fraction one derive from only four
patients.

Fraction
number
Planning

Mean V26 (%)

P value

1

47.5 ±12.1

0.15

5

37.1 ±17.9

0.01

10

37.0 ±17.5

0.03

15

36.2 ±16.7

0.01

20

37.0 ±17.8

0.08

25

33.9 ±16.4

0.01

30

35.6 ±16.8

0.02

35

33.5 ±15.5

0.03

40.6 ±15.6

Table 6.3. Mean V26 (+ standard deviation) of parotid glands with original IMRT plan.
Four patients only had data for fraction one.

6.2.2 IMRT Plan Adaptation
In the 22 adaptive replanning events, the parotid gland V26 value with the original IMRT
plan was compared to the V26 value obtained with adaptive replanning (Table 6.4).
Although the adaptive plans met the original parotid gland dose constraints, the
adaptive plan delivered a higher parotid gland dose compared to the original plan
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(p=0.001). This was due to a less rigourous examination of parotid gland dose when
undertaking IMRT plan optimisation at the time of plan adaptation. Less emphasis was
placed on maximal possible reduction of parotid gland dose, in order to achieve a rapid
turnaround time to commence a patient on the reoptimised IMRT plan.
Further retrospective replanning was therefore undertaken, with optimisation
parameters placing more importance on the parotid gland dose. This retrospective
replanning was able to obtain improved PTV coverage as well as a reduced parotid
gland dose (ART2 values in Table 6.4). The box and whiskers plot in Figure 6.3
demonstrates this improvement; the retrospective replanning events are named
“ART2”.

Mean
Standard
Deviation

Original plan
V26 (%)
37.8

ART1 V26
(%)
43.54

ART2 V26
(%)
34.29

15.1

16.4

13.5

<0.01

0.01

P value

Table 6.4. Mean V26 values of parotid glands for all replanning events; comparing the
original IMRT plan (Original) vs. adaptive replan (ART1) vs. retrospective replan
(ART2). The p values compare the replans (ART1 and ART2) with the original IMRT
plan.
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Figure 6.3. Comparison of mean coverage of (a) Parotid Gland (V26) and (b) PTV70
(V95) for the original plan (Original) vs. the adaptive plan used for treatment (ART1) vs.
the retrospective adaptive plan (ART2). The error bars represent the maximum and
minimum values.
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6.3 Dosimetric Changes in Spinal Canal
6.3.1 Original IMRT Plan
The spinal canal dose has been calculated in two ways. Firstly, the volume (in mL) of the
contoured spinal canal receiving >45 Gy; secondly the maximum dose to the spinal canal
(to a volume of 0.1 mL). There is no trend seen with how the dose to the spinal canal
changes during treatment (Table 6.5). Whilst there were isolated significant results at
fractions 10, 25 and 35; these results are insufficient to draw any conclusions. The data
for fraction one derive from only four patients.

Fraction
number

Volume
>45Gy (mL)

P value

Max dose
(cGy)

P value

Planning

0.3 ±0.6

1

0.4 ±0.7

0.31

4761 ±558

0.25

5

0.6 ±0.9

0.07

4809 ±652

0.54

10

0.6 ±0.9

0.05

4898 ±904

0.01

15

0.9 ±1.2

0.11

4974 ±686

0.06

20

0.7 ±1.1

0.14

4793 ±557

0.67

25

0.9 ±1.0

0.04

4980 ±644

0.24

30

0.8 ±1.4

0.25

4709 ±565

0.96

35

0.8 ±1.1

0.06

4982 ±812

<0.01

4691 ±983

Table 6.5. Volume of spinal canal receiving >45 Gy and maximum dose to spinal canal (+
standard deviations) with original IMRT plan. Four patients only had data for fraction
one.

6.3.2 IMRT Plan Adaptation
In the 22 adaptive replanning events, the spinal canal dose on the original IMRT plan
was compared to the dose obtained with adaptive replanning (Table 6.6). There was a
significant reduction in spinal canal dose with adaptive replanning, compared to the
original IMRT plan; both in terms of volume of spinal canal receiving >45 Gy and
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maximum spinal canal dose. The maximum spinal canal dose with adaptive replanning
was 5093 cGy compared to 5459 cGy with the original IMRT plan (p<0.01).

Mean

0.9

Volume
>45Gy,
Adaptive
plan
0.4

Std deviation

1.1

0.6

Volume
>45Gy,
Original plan

P value

0.01

5459

Max dose
(cGy),
Adaptive
plan
5093

821

820

Max dose
(cGy),
Original plan

<0.01

Table 6.6. Volume of spinal canal receiving >45 Gy and maximum dose to spinal canal for
all 22 replanning events; comparing the original IMRT plan vs. adaptive replan. The p
value compares the adaptive replan with the original IMRT plan.
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Chapter 7
Summary of Research, Discussion
and Conclusions
7.1 Restatement of Project Aims and Research Questions
The two aims of this project were:
Aim 1. Investigate the anatomical changes occurring in a cohort of patients during H+N
radiotherapy.
Aim 2. To investigate the impact of anatomical changes on dose delivery to the Target
Volumes, parotid glands and spinal canal; and the impact of IMRT plan adaptation on
subsequent dose delivery to these structures.
The following research questions have addressed these aims:
Aim 1.
a. What volumetric changes are observed in the Target Volumes during H+N
IMRT?
b. What volumetric and geometric changes are observed in the parotid and
submandibular glands during H+N IMRT?
c. Are any changes in subcutaneous fat volume detectable during H+N IMRT?
Aim 2.
a. What doses are delivered to the PTVs, parotid glands and spinal canal during
unadapted H+N IMRT?
b. What is the impact of plan adaptation on the PTV dose, parotid gland dose
and spinal canal dose?
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c. Do any factors correlate as predictors of when the IMRT plan requires an
adaptation?
In answering these research questions, the goal has been to add to the body of
knowledge on anatomical changes occurring within the head and neck region during
head and neck cancer RT and to explore how ART may be best utilised to improve our
treatment delivery in this cohort of patients. There is a balance to be gained between
clinical gain and resource use, especially in terms of additional time spent in
implementing ART by the various professionals involved in the RT process. There is a
willingness to embrace new technology in radiation therapy, and the implementation of
new technology should be accompanied by a thorough quantitative investigation of its
actual benefit. As a result of this project, it is hoped that further research questions can
be generated and subsequently investigated.

7.2 Summary of Research
7.2.1 Volumetric Changes Observed in the Target Volumes
during H+N IMRT
The tumour volumes were demonstrated to reduce in volume over the treatment period,
with the exception of the CTVn0 (representing the uninvolved, but at-risk nodal region)
and the PTV60 (low dose PTV). At fraction 35, the nodal volume (GTVn) had greater
volume reduction (44 %) compared to the primary tumour volume (GTVp) (25 %). It is
hard to compare these results to the existing literature, as there is variation in the
timings of when volumes are measured as well as which tumour volumes are measured
(section 2.2). CT studies reporting primary tumour volume reduction at the end of RT
report ranges of 17 to 80 % in volume reduction; results from this investigation fall
within these parameters.
Of the 4 patients who underwent an additional CT scan at fraction 1, an increase in
tumour volume was observed between the planning CT scan and the start of treatment.
For the two patients who needed plan adaptation at fraction one, there was a larger
increase in tumour volume, which translated to larger increases in PTV volumes (both
PTV70 and PTV60) compared to the two patients who did not need plan adaptation.
This suggests that minimising the interval between treatment planning and
commencement of treatment is important in some patients; emphasising the need for
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adequate resources to ensure that the treatment planning process can proceed with
minimal delay.

7.2.2 Volumetric and Geometric Changes Observed in the
Salivary Glands during H+N IMRT
The parotid glands showed a volume reduction of 28 % by the end of RT; similar to the
published average volume reduction of 26 % obtained from an analysis of multiple
studies (48). Significant volume reduction was observed from fraction five. Whilst some
authors report a greater volume reduction in the first half of treatment, compared to the
second half, this investigation has not shown this trend. Comparison of ipsilateral versus
contralateral parotid gland volume reduction has not been made in this investigation, as
all patients received bilateral neck treatment. In terms of parotid gland shift, a small
medial shift of 1.2 mm of the lateral portion of the gland was demonstrated by fraction
35. The whole parotid gland did not demonstrate a significant shift. This is a smaller
magnitude of shift than what is reported in the literature, as discussed in section 2.3.1. It
could be accounted for by set-up uncertainties and averaging of geometric shifts in
varying directions for different patients, discussed further in section 7.3.5.
The submandibular glands demonstrated significant volume reduction from fraction
five, with a total reduction of 26 % by the end of RT. Again, this is similar to the average
volume reduction of 22 % acquired from pooling of data from multiple studies (48). A
greater volume reduction was observed in the first half of treatment, compared to the
second half of treatment; similar to other literature as discussed in section 2.3.2. An
average superior shift of 2.4 mm for the submandibular glands was observed by fraction
30 in this investigation; similar to what has been described by some other authors.
However, the method used in this investigation for measuring submandibular gland
movement was not as robust as the method used for measuring the parotid gland
movement, as discussed in section 3.4.5. This is a limitation of this analysis and should
be considered when interpreting the results.
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7.2.3 Changes Observed in Subcutaneous Fat Volume during H+N
IMRT
There was a significant loss of fat volume seen in fractions 20, 25 and 35, when fat
volume was measured on a single CT scan slice (Section 5.4). However, this result was
no longer significant when calculating fat volume on greater numbers of slices. The fat
volume loss noted on a single CT scan slice is unlikely to be an accurate representation
of true fat volume changes; as the single isocentre slice is less likely to be representative
of the entire fat volume. However, this section of the investigation is unique, as there is
no published literature on fat volume changes during H+N RT. It is worth considering fat
volume changes in future investigations, since weight loss during treatment would affect
the amount of fat present. The loss of fat volume in the head and neck region may alter
the positioning of the target volumes within the neck and hence impact dose delivery.

7.2.4 Dose Delivery to PTVs during Unadapted and Adapted H+N
IMRT
A significant reduction in dose to the PTV70 and PTV60 was observed from fraction five;
with unacceptable dose delivery to the PTV70 from fraction five and to the PTV60 from
fraction 20. Plan adaptation resulted in a significant improvement in dose delivery to
both the PTV70 and PTV60.
The published literature is not consistent in reporting the dosimetric variations to
tumour target volumes; with some authors reporting both underdosing of tumour
volumes and increased dose homogeneity, whilst other authors report no underdosing
to the tumour volumes. Similarly, the effect of plan adaptation on tumour volume
coverage is also not consistently reported, with some authors reporting improved dose
delivery and others reporting no improvement. The limitations of comparing the
published literature on this aspect have been discussed in section 2.7.1.

91

7.2.5 Dose Delivery to Parotid Glands during Unadapted and
Adapted H+N IMRT
This investigation demonstrated a reduction in parotid gland dose (mean V26) if
patients received unadapted treatment. At planning, the mean V26 value for all parotid
glands was 40.6 %; reducing to 33.5 % at fraction 35. This finding is different to what
the literature in general has described; that unadapted treatment results in higher
parotid gland dose than what was originally planned. Brouwer et al (48) report an
average increase in mean dose of 2.2 Gy to the parotid glands. Only two other studies
have demonstrated similar findings to this investigation, i.e. no increase in parotid gland
dose delivery with unadapted treatment. In one study (31), most patients did not have
nodal disease in the neck and in the other study (21), most patients had either received
neoadjuvant chemotherapy to reduce bulky disease in the neck or had undergone a neck
dissection prior to radiation therapy. Given this observation, the difference between the
finding of this investigation and other published reports could be due to the differences
in the extent of nodal disease between the patient cohorts. Other factors affecting dose
delivery to the parotid glands could be differences in tumour site, beam arrangements
or daily set-up variations; discussed further in section 7.3.5.
In this investigation, although the adaptive plans met the original parotid gland dose
constraints, the adaptive plan delivered a higher parotid gland dose compared to the
original plan. This was because, in order to rapidly commence a patient on the
reoptimised IMRT plan, less emphasis was placed on minimising parotid gland dose
when undertaking plan adaptation. The first acceptable adaptive treatment plan in
terms of PTV coverage was utilised. However, on retrospective replanning (ART2), it
was demonstrated that plan adaptation could result in a reduction in the mean V26 of
the parotid glands reduced parotid gland dose delivery (whilst still maintaining
acceptable PTV dose delivery); consistent with other published literature. IMRT plan
optimization parameters for the parotid glands should be adjusted for adaptive
replanning, in order to keep the parotid gland dose below that for the original plan.
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7.2.6 Dose Delivery to Spinal Canal during Unadapted and
Adapted H+N IMRT
There was no significant increase in spinal cord dose during H+N RT for the unadapted
plans; though isolated significant increases were noted on 3 occasions. This differs to
reports in the literature, with a general consensus that unadapted treatment results in
the spinal cord receiving a higher dose than planned. Some investigators have also
reported that a proportion of patients exceed the spinal cord tolerance doses (18,20)
with unadapted treatment.
In this investigation, IMRT plan adaptation resulted in reduced spinal cord dose (both
volume receiving >45 Gy, and maximum spinal cord dose); which corresponds with
other published reports.

7.2.7 Correlations with Need for Plan Adaptation
Whilst there was significant weight loss in the patient cohort during the treatment
course, weight loss did not correlate with a change in PTV coverage. Nutritional status
also deteriorated during the treatment course, as seen by an increase in the PG-SGA
score. However, the nutritional score did not correlate with change in PTV coverage
either. However, this investigation has a small number of patients and it is unlikely that
any significant correlation would be identified. Further larger scale investigations would
be required in order to examine this question further.
However, a significant correlation between initial nodal volume and the number of plan
adaptations was identified. It would make sense that patients with a higher volume of
nodal disease in the neck would require more plan adaptations, as anatomical changes
due to nodal shrinkage would lead to alterations in dose delivery within the neck.
Numerous correlations with dose delivery to tumour structures and OARs have been
investigated and results reported in the published literature. These investigations often
involve small patient populations, with the identification of measures of plan
inadequacy not being the primary objective of the study. Although some statistically
significant findings are reported (Section 2.8.2), correlations are often weak and no
single factor stands out from the numerous correlations reported.
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7.3 Discussion
This investigation raises issues worthy of discussion in several areas:
i.

The impact of an ART protocol on departmental resource allocation

ii.

The accuracy and consistency in contour delineation for weekly CT scans

iii.

The management of shrinking tumour volumes

iv.

The use of PTV or CTV for assessment of tumour dose delivery

v.

Interpretation of dosimetric results

vi.

Optimal frequency and timing of imaging and adaptive planning

vii.

Strengths and limitations of this investigation

viii.

Recommendations for an ART protocol

ix.

Potential future directions for research.

7.3.1 Impact of this Protocol on Departmental Workflow and
Resource Allocation
The implementation of this ART protocol resulted in a significant change in how the 10
enrolled HNC patients received their radiation treatment, compared to unenrolled HNC
patients. The default departmental policy was to trigger re-imaging with a planning CT
scan if the patient immobilisation mask was noted to be looser or contain large air gaps,
or if there had been a significant reduction in clinically apparent nodal disease.
Implementing the investigation protocol, using conventional planning CTs, required
substantial additional resources, in terms of radiation oncologist, radiation therapist
and physicist time. Therefore, the department embarked upon a steep learning curve in
terms of optimising workflow and delivering this protocol in an efficient manner.
In this investigation, the goal was to achieve a turnaround time of 24 to 48 hours for
assessment of the treatment plan dose distribution and undertaking plan adaptation (if
required). It took approximately one hour for CT scan acquisition, rigid registration and
dose recalculation. The subsequent delineation of contours took a median time of 240
minutes for the original planning CT scan, and 180 minutes for subsequent scans. By
contrast, other publications report physician contouring times of between 44 to 150
minutes (38,80,81,95). This timing can vary widely depending on the amount of
structures contoured and physician experience. The reoptimisation of treatment plan,
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dosimetry and Quality Assurance procedures were not measured for this investigation,
but took approximately one working day to complete.
With the first patient, the first adaptive plan could not be delivered within a 24 to 48
hour turnaround time. However, within a short time, efficiency had improved and it was
possible to re-contour, assess and perform plan adaptation (if required) within a 24 to
48 hour turnaround time. By contrast, Schwartz et al report a median of two days (range
one to four) from CT imaging to delivery of an adapted treatment plan (23). Achieving
this turnaround time required good communication and co-ordination between the
various staff members involved. However, the impact on staff time meant that the
departmental resources allowed for only one patient at a time to be enrolled on the
protocol. Clinical implementation of this protocol, involving weekly imaging and plan
assessment, in all HNC patients was beyond the capability of the department. However,
this exploratory protocol was important in helping to develop recommendations for
implementing a more practical ART policy for all HNC patients. Additionally, the lessons
learnt from undertaking this investigation meant that all subsequent H+N patients
benefited, as the HNC RT planning process substantially improved in terms of planning
time and techniques.

7.3.2 Contouring Accuracy and Consistency
The initial accuracy of TV definition is of major importance, since it can potentially affect
patient clinical outcome. Peters et al (96) reported on the impact of radiotherapy quality
on clinical outcome in a large international phase three study. Major deficiency in the
treatment plan was associated with a 20 % reduction in overall survival. Approximately
one quarter of these major deficiencies were due to inadequate identification of the GTV.
In this investigation, GTV definition on the initial planning CT scan used information
acquired from clinical examination, as well as information from other imaging
modalities such as the diagnostic CT scan, FDG-PET and MRI imaging.
Consistency in weekly contouring was an essential component of this investigation, as
the calculation of volume change and subsequent dose delivery to contoured regions
relied on this. Therefore, all contours were manually performed by a single radiation
oncologist, in order to eliminate interobserver variability, and validated by a second
radiation oncologist. Intraobserver variability was minimised by adhering strictly to
international consensus guidelines for contouring (88) and ICRU 62 definitions (89).
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Following these guidelines and the ICRU definitions ensured that contouring was
performed by adhering to anatomical boundaries, rather than a “Picasso approach” to
contour generation. A formal assessment of intraobserver variability was not
undertaken for this investigation. During the contour definition process on the initial
planning CT scan, annotations of contour placement decisions were also made, to
improve consistency in weekly contouring and further minimise intraobserver
variability. This was especially useful when contouring the GTVp each week. The use of
annotations had the additional benefit of reducing weekly contouring time.
Whilst the original planning CT scan utilised i.v. contrast; subsequent planning CT scans
were non-contrast studies, in order to reduce inconvenience to the patient (of weekly
intravenous access) and to reduce the risk of i.v. contrast-related reactions. It was more
challenging identifying the tumour boundaries on a non-contrast CT scan, especially for
the GTVp as there is less difference in CT density between the primary tumour and
adjacent normal tissue (unless the tumour is adjacent to bone or air). However, the
annotations of contouring placement decisions assisted significantly in the weekly
contouring process, especially with respect to the primary tumour volume.

7.3.3 Shrinking Tumour Volumes
There is a lack of evidence about how to delineate a shrinking target volume during the
course of RT. When the tumour shrinks, a reduction in treatment volume should reduce
toxicity, but this is a futile gain if the reduction also results in recurrence. The CTV
around a tumour is seemingly “uninvolved tissue” but may still contain large numbers of
viable tumour cells. If alterations for a shrinking tumour are inadequate; tumour
recurrence may result from inadequate radiation dose being delivered to areas of
subclinical disease. In a recent publication by Hamming-Vrieze et al (43), eight patients
with oropharyngeal tumours had fiducial markers implanted in the tissue at the
periphery of the primary tumour. These fiducial markers were used as a surrogate to
investigate the behaviour of tissue surrounding the GTV edge. Marker displacement
relative to the GTV surfaces was examined using daily CBCT and MRI scans (at weeks
three and six). The authors concluded that reducing the CTV volume mid-treatment (by
following GTV reduction) risked under-dosing microscopic disease. They concluded that
adjusting CTV volumes to “clear anatomical boundaries” was a safer approach to
managing shrinking tumour volumes.
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Hansen et al (42) described their approach to avoid under-treating microscopic disease,
as the GTV shrinks. They maintained the original GTV volume on the second CT scan,
with some modification to anatomical boundaries (such as air and skin) only. The
second mid-treatment CTV volume was reported to decrease by 7.5 % due to weight loss
and/or tumour and nodal shrinkage. Zhao et al (35) modified subsequent GTVs
according to their shrinkage, but maintained the size of the original CTV contours. Other
authors describe their approaches where GTVs were modified to the air/tissue
interface and CTV/PTV contours were generated by maintaining the original contours
with adjustments at the skin surface or at boundaries with adjacent normal structures
(24,59). Several authors emphasise the importance of maintaining the prescribed dose
to the pretreatment volumes (20,31,97,98), but without giving specific strategies for
generating contours in the presence of shrinking tumour volumes.
In this investigation, it was decided to delineate the CTVp volumes on the weekly CT
scans according to clear anatomical boundaries, in order to reduce the risk of
undertreating microscopic disease. As detailed above, this approach is now
recommended in the publication by Hamming-Vrieze et al (43). In terms of delineating
shrinking nodal volumes (CTVn), a different contouring approach was required as the
nodes are located in the soft tissue, often with distant anatomical boundaries. Unlike the
primary tumour volume, there is no evidence to guide the delineation of shrinking nodal
volumes. Three different strategies were discussed prior to patient enrolment in this
investigation. These strategies, summarised in Figure 7.1, were:
i.

Constant Expansion Margin
This approach applies a constant 3 mm GTVn to CTVn expansion margin
whenever the CTVn is generated. As the lymph node reduced in size,
surrounding soft tissue would move inwards and be incorporated by the
expansion margin. However, a smaller volume of soft tissue would be covered
within CTVn as the lymph node reduced in size.

ii.

Fixed Expansion Position
This approach applies a variable expansion margin so that there is a fixed CTVn
margin position; resulting in a larger volume of soft tissue being incorporated
into the CTVn volume as the lymph node reduced in size.

iii.

Fixed CTV Volume
This approach calculated the non-GTVn CTVn volume and calculates a new
expansion margin to maintain a fixed volume of soft tissue within the CTVn as
the lymph node reduces in size. This complex volumetric approach would
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require an individualized margin for each node in each patient, as the rate of
volume reduction could vary between nodes.

Figure 7.1. Three options, considered for this investigation, for contouring shrinking
nodal volumes (CTVn) on weekly imaging.

98

The first option was selected for this investigation; i.e. the CTVn was contoured each
week by maintaining a 3mm margin around the visible lymph node (GTVn). This was felt
to be a reasonable and practical approach, as all of the soft tissue surrounding the lymph
nodes would be either a component of the CTVn or the CTVn0 (at risk area treated to 60
Gy). The CTVn0, containing at risk soft tissue, was contoured according to anatomical
boundaries on each weekly scan.
Tumour shrinkage was noted as treatment progressed; with a significant volume
reduction of 24.6 % in the GTVp and 44.3 % in GTVn (Table 5.1). The corresponding
CTVp and CTVn volumes also reduced in volume. For the primary tumour, most of the
18.0% reduction in CTVp volume was due to visible tumour volume reduction (Table
7.1); the volume of surrounding soft tissue contributing to the CTVp (i.e. CTVp volume –
GTVp volume) only reduced by 4.4 % by fraction 35. Therefore contouring a shrinking
CTVp along anatomical boundaries resulted in a consistent volume of tissue
incorporated in this contour.

Fraction
number

Volume (ml) of normal tissue in
CTVp
[CTVp minus GTVp],
Vol change from planning (%)

Volume (ml) of normal tissue in
CTVn
[CTVn minus GTVn],
Vol change from planning (%)

Planning

29.7mL

32mL

5

29.8, +0.3

32.3, +0.9

10

27.8, -6.4

31.2, -2.5

15

28.8, -3.0

30.5, -4.7

20

27.2, -8.4

27.6, -13.8

25

28.6, -3.7

27.2, -15

30

30.6, +3.0

26.6, -16.9

35

28.4, -4.4

26.4, -17.5

Table 7.1. Volume change in soft tissue comprising CTV volumes over the treatment
course.

However, due to the different method for contouring shrinking nodal disease, the
reduction in volume of soft tissue surrounding the lymph nodes (i.e. CTVn volume –
GTVn volume) contributed to 17.5 % of the total 28.1 % volume reduction in CTVn
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(Table 7.1). In other words, the 3 mm margin around the GTVn covered a smaller
volume of soft tissue compared to the initial planning CT. The previously included soft
tissue fell outside the CTVn boundary and therefore became a component of the CTVn0.
The CTVn0 volume did not demonstrate a significant volume reduction as treatment
progressed (Table 5.1).
Whilst the clinical impact of the method used in this investigation for contouring
shrinking nodal volumes cannot be compared to other investigations, it is worth noting
that no nodal recurrences were observed in follow up of the patient cohort. However,
the management of contouring shrinking nodal and primary tumour volumes in an area
worthy of further investigation.

7.3.4 The Use of PTV or CTV for Assessment of Tumour Dose
Delivery
This investigation used the PTV volumes (PTV70, PTV60) to assess the adequacy of dose
delivery to the tumour and as a trigger for plan adaptation. There is a difference in
opinion amongst radiation oncologists as to whether the PTV or the CTV is the most
appropriate structure for an assessment of tumour dose delivery.
The CTV is a biological construct, which describes the extent of microscopic tumour
spread beyond the visible tumour (GTV). The CTV is defined according to boundaries
between different tissue planes and incorporates a clinical assessment of the risk and
extent of microscopic spread based on pathological data. The PTV, by contrast, is a
geometric construct incorporating the CTV, which accounts for random and systematic
uncertainties in treatment delivery (set-up margin) as well as a margin for tumour
motion (internal margin). Unlike the CTV, the PTV cannot and should not be adjusted
according to clinical circumstances (e.g. patient anatomy where a critical OAR is in close
proximity). The ICRU62 (89) recommends that radiotherapy dose is prescribed to the
PTV and the PTV should be used when reporting dose delivery. Therefore, it makes
sense that if the PTV is the volume that is used to determine whether the initial
treatment plan is suitable; it should also be the volume used to assess the ongoing
suitability of the treatment plan. This is the rationale behind the use of PTV dose to
determine the need for plan adaptation in this investigation. Other authors have also
described dose to the PTV (11,18,20,24–27,40,42,58); as described in sections 2.4 and
2.7.1. Ahn et al (18) report their TV and OAR parameters which triggered plan
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adaptation. The PTV parameters were identical to the parameters used in this
investigation, i.e. D95 <95 % of the prescription dose.
The selection of PTV margin is based on departmental data as per institutional IGRT
protocol. This was determined via a prior departmental investigation and implemented
for all Head and Neck cancer patients. The PTV margin used for this investigation is
similar to the margin used by Schwartz et al (23,77). However, Schwartz et al used a
0mm margin for PTV contour generation on the rescans. The 3mm margin, for weekly
PTV contour generation, used in this investigation is a conservative margin in
comparison. The selection of PTV margin is further supported by other investigators
(40,99), whereby a 3mm margin for PTV generation was not inferior to a 5mm in terms
of clinical outcome or target volume dose coverage.

7.3.5 Interpretation of Dosimetric Results
Whilst dose calculation on repeat imaging studies is performed and reported widely,
interpretation of the data needs to consider causes for variability in the results. Some
variability between studies may be due to differences in the patient population (for
example, disease site and staging) or treatment factors, such as variations in beam
arrangement and whether RT is delivered post-operatively or in the definitive setting,
without or without neoadjuvant or concurrent chemotherapy. Robar et al (ref 58) and
Hansen et al (ref 42) report that parotid gland dose changes were not consistent
between the right and left parotid glands. In the investigation by Robar et al (ref 58),
there was significant increase in dose delivery to the parotid gland on the left side only.
They suggest that this variability could arise due to differences in tumour location and
size, or due to IMRT beam arrangements. Rotational set-up errors could also account for
these variations, as discussed later in this section. Other differences in the patient
population may arise due to the movement of interstitial fluid, resulting in tissue
deformation. This could impact dose delivery and may vary during treatment (85).
Kagar at al (54) report the parotid gland displacement due to pre-chemotherapy
hydration; with a lateral displacement seen in the immediate days following
chemotherapy administration and a medial displacement observed thereafter.
This investigation demonstrated a reduction in parotid gland dose (mean V26) during
the course of radiation therapy if patients had received unadapted treatment. This
finding is different to what the literature in general has described (as discussed in
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section 2.5.1); that unadapted treatment results in higher parotid gland dose than what
was originally planned. In this investigation, two of 10 patients had no visible nodal
disease in the neck. Given this observation, the difference between the finding of this
investigation and other published reports could be due to the differences in the extent of
nodal disease between the patient cohorts. Similar to this investigation; two studies
(21,31) also reported no increase in parotid gland dose. In the investigation by Height
et al (31), only four of 10 patients presented with lymph node disease in the neck; other
studies tend to report greater numbers of patients with nodal disease. Similarly, in the
study by Ho et al (21), the majority of patients had either received neoadjuvant
chemotherapy to reduce bulky disease in the neck or had undergone a neck dissection
prior to radiation therapy and therefore had reduced nodal disease. It is quite plausible
(though not conclusively demonstrated by these 2 studies) that the extent of nodal
disease could result in variability in dose reporting to the parotid glands.
Variability in contour delineation may introduce variations in dose deposition. Feng et al
(100) studied the dosimetric impact of contouring variability in OARs in the H+N. A
mean difference of 0.9 Gy (range 0.6- 1.1Gy) was reported due to the spatial differences
in contour generation between different observers. With respect to tumour volumes in
the H+N, contouring variability has been reported (101), however there is no data
reporting the dosimetric impact of this variability. In this investigation, contouring
variability was minimised by using a single observer to perform all contour generation,
with a second observer to check the subsequent contours. Additionally, the image
registration process may introduce random and systematic variability, which could
impact on results of contour shift and dosimetric comparison (102).
Interfraction positional variation of the patient also has a significant effect on dose
delivery; the magnitude of which is reduced with daily imaging and set-up corrections
(103). Siebers et al (104) reported dose deviations to the GTV of ≥ 3 % in 11 % of their
HNC patient sample as a result of random and systematic errors in patient set-up;
though only 2 % of the patient sample had dose deviations of ≥ 5 %. Delana et al (105)
quantified the impact of set-up variations on parotid gland dose. A 3 % increase in mean
parotid dose was observed with each millimetre displacement in the craniocaudal and
lateral dimensions; displacements in the anteroposterior dimension had a smaller
impact. Ahn et al (18) report significant correlations between positional variation and
dose delivery to parotid glands, target volumes, spinal cord and mandible. Han et al (49)
demonstrated an increase in spinal cord Dmax of up to 0.5 Gy if daily set-up corrections
were not undertaken. Hunter et al (61) highlighted the individual patient variability in
102

dose to the parotid glands; with some glands showing an increase in dose, and others a
reduction in dose. In glands where a reduction in dose was noted, the contralateral
gland received an increased dose; suggesting that rotational set up deviations
contributed to alterations in dose delivery. Rotational set up deviations were not
corrected for in their investigation. Set-up corrections in the craniocaudal,
anteroposterior and lateral planes are regularly performed; however, in order to correct
rotational set-up variations, a specialised couch is required (106).

7.3.6 Frequency of Imaging and Adaptive Replanning
The frequency of dosimetric evaluation in this investigation is similar to the study
published by Schwartz et al (23), where 24 patients underwent daily in-room CT
scanning with weekly dose calculation on contours created by deformable-image
registration technique. All patients required at least one replan due to “CTV and normal
tissues changes”. However, underdosing of the CTV was not observed, suggesting that
replanning was required due to excessive OAR dose. By contrast, this investigation
demonstrates inadequate PTV coverage in 80 % of the patient cohort (8 of the 10
patients), requiring IMRT plan adaptation during the course of treatment. Plan
adaptation was required due to inadequate PTV coverage in all cases, rather than
excessive OAR dose.
Other investigators (18,20,76) have reported lower rates of plan adaptations than what
is reported in this investigation; however the frequency of CT scanning and dosimetric
analysis in these reports is less than weekly. Ahn et al (18); re-imaged at three time
points during the treatment course; and demonstrated that 65 % of their patients (15 of
23) required replanning, predominantly due to inadequate PTV coverage. Wang et al
(76), undertook a single re-imaging at fraction 25, and reported that 50 % of unadapted
plans were noncompliant for OAR dose criteria. Jensen et al (52) report that 21 % of
their cohort required plan adaptation, however this decision was based on an
assessment of differences in contour overlay, rather than a dosimetric evaluation.
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7.3.7 Timing of Adaptive Replanning
Significant changes in anatomy occurring in the first half of treatment have previously
been reported (48), with greater volume loss occurring in the parotid and
submandibular salivary glands during the first half of treatment compared to the second
half. This has been discussed in greater detail in sections 2.3.1 and 2.3.2. Furthermore,
section 2.5 discusses how significant dosimetric alterations to OARs, have been
identified early in the 35 fraction radiation therapy course.
Given the demonstration of significant dosimetric alterations occurring early in the
treatment course, with subsequent benefit of plan adaptations; many authors have
recommended that an ART protocol should be implementing repeat imaging and plan
adaptations in the first half of treatment (Section 2.8.3, Table 2.6) (18,20,25,48,59,86).
Schwartz et al (23), who performed weekly dose calculations, report that the median
timing of first replan for their cohort was at fraction 16. Bhide et al (11) demonstrated
significant changes in PTV coverage by week two of radiotherapy; however their patient
cohort had also undergone induction chemotherapy, which would have affected tumour
volume prior to commencement of radiation therapy.
In this patient cohort, adaptive replanning was required early in the 35 fraction course
of radiation therapy. 41 % of replanning events occurred at or before fraction 10; and
more than half events had occurred by fraction 15. All first IMRT plan adaptations and
half of the second plan adaptations had occurred by fraction 15. This suggests that
inadequate IMRT plan dosimetry can occur early and due to changes too subtle to be
detected by assessing mask fit. However, there was also a need to perform plan
adaptations till the very end of the treatment, with four plan adaptations (18 % of the
total) required at fraction 30.

7.3.8 Strengths of this Investigation
The strengths of this investigation lie in the weekly planning CT scans, which allowed for
regular assessment of the “actual” dose delivery as anatomical changes occurred. DVH
parameters were prospectively set to indicate unacceptable dose delivery and as a
trigger for plan adaptation. This permitted a truly adaptive approach to be implemented
as patients were treated with a re-optimised plan, within 48 hours of the CT scan
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demonstrating unacceptable dose delivery. An advantage of using standard fan beam CT
is ease of dose calculation (92). Cone beam CT may be subject to a number of image
artefacts that complicate accurate dose calculation (i.e. reduced field of view, scatter
causing unstable Hounsfield Unit numbers, ring artefacts etc.) (107).
An additional strength of this study is that manual contour delineation of all structures
was performed, which currently is superior to the use of contour propagation via
deformable image registration and autosegmentation software, especially for the GTV
and CTV volumes. The use of automated contour propagation is appealing, as it can save
time compared to manual contour delineation. Publications report a 30 to 40 % time
saving in the contour delineation process using an Atlas Based Autosegmentation
technique (108–110). This can be significant, especially as contour delineation in HNC
can take up to 44 to 144 minutes on average (80,81,95); and longer for less experienced
physicians. However, the use of automated contour propagation has several limitations.
Its accuracy is very dependent on the similarities between the atlas used and the
anatomy of the patients. The automatically propagated contours are limited by the fact
that repeat imaging generally does not use i.v. contrast. Additional limitations arise from
the presence of dental artefacts, as well as the deformations in normal anatomy in
patients, due to tumour or nodal enlargement. Automatically propagated contours
usually require editing by the physician, in order to be suitable for planning use
(97,108,109,111). GTV and CTV volumes (both primary tumour and nodal) need greater
correction than OARs. Some OARs require little or no editing, for example the spinal
cord and mandible; others require a degree of editing especially where there is less
contrast between the soft tissue planes, for example the submandibular glands
(108,111,112).

7.3.9 Limitations of this Investigation
Despite having a large number of CT scans to evaluate (total 84); with a patient cohort of
10, this is considered an exploratory investigation of an ART protocol. Comparison of
the results presented in this thesis with other published literature or by performing a
larger study is recommended when instituting an ART protocol for HNC treatment.
Weekly imaging and analysis is a resource intensive process, therefore other
investigators undertake either a protocol with larger patient numbers and a lower
frequency of imaging; or smaller patient numbers if weekly imaging is performed. Other
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prospective reports, incorporating weekly imaging, have enrolled 11 to 20 patients
(23,25,41,59,77).
Additionally, the weekly CT scans were non-contrast scans, to reduce patient
inconvenience and risk. Whilst the use of i.v. contrast for the weekly CT scans would
have been gold standard for weekly comparison, the potential risks associated with
weekly i.v. contrast administration had to be taken into account for this protocol.
However, contours were able to be delineated quite confidently on the non-contrast CT
scans, as the original planning CT scan (with i.v. contrast) was referred to, assisting with
consistent contour delineation.
A formal assessment of intraobserver variability was not undertaken for this
investigation. However, intraobserver variability was minimised by adhering strictly to
anatomical boundaries and the use of published contouring guidelines when contouring.
Additionally, notes were made when contouring on the planning CT scan, to ensure
consistency across contouring on the weekly CT scans. Only two authors of the
numerous papers cited in this thesis have performed a formal assessment of
intraobserver variability (11,22); both reported that intraobserver variability was nonsignificant. Ricchetti et al (22) reported that the greatest intraobserver variability was
seen for the submandibular glands and larynx in their study. Interobserver variability
may have affected the volume changes observed in this investigation and should be
considered when interpreting the data.
A further limitation is that some of the data analysis was performed retrospectively,
some years after the initial analysis and patient treatment. This meant that some
analysis was no longer possible to perform, for example NTCP modelling, due to
technical issues regarding the restoration of patient data onto the treatment planning
system. One patient’s data were also lost, so the additional retrospective analysis is
missing some data points.

7.3.10 Recommendations as a Result of this Investigation
The findings of this investigation result in some recommendations being made for ART
implementation.
i.

An ART protocol should be implemented for all HNC patients undergoing
definitive radiation therapy; 80 % of the patient cohort required one or more
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plan adaptations and no recommendation can be made for selecting patients at
highest risk for inadequate dose delivery.
ii.

Imaging and assessment of dose delivery should be undertaken at multiple time
points during the course of RT; as often as departmental resources allow.

iii.

Patients with a large initial volume of nodal disease should be considered for
more frequent imaging and plan assessment.

iv.

The first repeat imaging and plan assessment, to new contoured volumes,
should occur early in the treatment course, as early as fraction 5 or 10.

v.

Repeat imaging and plan assessment should also be undertaken later in the
course of RT, e.g. at fraction 25, as suboptimal dose delivery can still occur at
this stage.

vi.

Good communication and teamwork are essential in streamlining the ART
process and ensuring a rapid turnaround time for a new treatment plan to be
delivered.

7.3.11 Future Research Directions
As a result of this investigation, suggestions for future investigations to build on this
work are made. These include the investigation of:
i.

Other imaging modalities to assess plan adequacy and a need to perform plan
adaptation, e.g. Cone Beam CT imaging, MRI imaging.

ii.

How autosegmentation software could be best employed to increase efficiency in
contour delineation.

iii.

The best process for delineating shrinking target volumes in the neck, in order to
avoid undertreating microscopic disease as tumour shrinkage occurs.

iv.

The impact of an ART protocol on clinical outcomes, e.g. xerostomia, quality of
life and tumour control, in larger prospective studies.

v.

Factors which could predict the need for plan adaptation. The PG-SGA should be
considered for larger prospective investigations, as one of its components is
patient weight.
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7.3.12 A Cone Beam CT Imaging Protocol
CBCTs are in widespread use for head and neck cancer radiotherapy, to improve the
accuracy of dose delivery, via daily online verification of patient positioning.
Additionally CBCT imaging can be utilised for dose calculations of both target volumes
(113–115) and OARs (21,60,113–115) during the course of RT; to assess changes in
dose delivery from the initial planning CT. The use of CBCT scans in ART has some
advantages:
i.

Minimal additional “on-table” time to acquire a CBCT.

ii.

The patient is already in the treatment position, and this reduces variability in
patient positioning, compared to the repositioning required to obtain a
conventional planning CT scan.

iii.

Dose calculation can be performed on CBCT image sets by applying appropriate
corrections for Hounsfield Units.

iv.

The validity of automated software approaches to delineation and planning to
achieve daily ART can be assessed and implemented.

However, routine CBCT use for the assessment of patient anatomy and dose delivery is
currently limited for several reasons. Firstly, the quality of CBCT images, in terms of soft
tissue definition, is not sufficient for the accurate delineation of certain contours, for
example the GTV and at-risk nodal areas (21,116,117). Although some investigators
have reported that CBCT images are of sufficient quality to outline many structures in
the H+N (21,113,118) for dose evaluation purposes, conventional planning CTs are still
required when undertaking a treatment plan adaptation. Researchers at one unit have
described a protocol utilising high dose CBCT imaging for dosimetric evaluation, due to
the superior soft tissue detail when compared to the lower dose CBCT used for daily
IGRT (21). Secondly, the field length for the CBCT is shorter than conventional planning
CT, and therefore the full head and neck field cannot be imaged in a single CBCT.
However, some centres have developed in-house software to combine two CBCTs to
allow for a more thorough assessment of the patient anatomy and dose delivery
(113,115).
Whilst there are multiple reports of phantom studies comparing the dose calculations
between CBCT and conventional planning CT, there are few comparisons in patients. In
two studies comparing dose calculations in both phantoms and HNC patients, the CBCT
108

and conventional planning CT dose calculations varied by +/- 3 % (replicating what has
been reported in phantom studies); however it is worth noting that the number of
patients investigated in each study was two (113,119). This may currently limit the use
of CBCT images for dose calculation.
A retrospective study compared the concordance of contours created manually by the
radiation oncologist on the conventional planning CT (obtained after the delivery of 40
or 50 Gy) with the contours generated via a deformable image registration method on
the CBCT obtained at the same time, use Dice Similarity Coefficient (DSC) analysis (118).
Good concordance was demonstrated for the mandible and parotid glands (Median DSC
0.8), whereas the nodal GTV was not as reliably replicated on the CBCT (Median DSC
0.55) due to poor image resolution.
As a result of this investigation, a protocol concept for evaluating the use of CBCT images
in an ART protocol is in development. This protocol aims to build on prior knowledge of
the use of CBCT in ART for H+N cancer. It will assess the feasibility of CBCT to determine
RT plan quality compared to conventional planning CT scan. A comprehensive
comparison of the volumes of the contours generated on the 2 image sets will add
valuable information to the already published literature. In addition, a comparison of the
time taken to assess RT plan quality for both CTs will provide a useful insight into the
likely benefit in terms of resource use. This concept outline for this proposed study is
attached as Appendix 3.

7.4 Conclusions
Due to the small cohort of patients, this investigation is regarded as an exploratory
study. However, the findings add to the literature supporting the use of an ART protocol
for HNC patients. Inadequate PTV coverage was demonstrated in 80 % of the patient
cohort, requiring one or more adaptations of the IMRT plan during the course of
treatment. In all cases, IMRT plan adaptation was required due to inadequate PTV
coverage, rather than excessive Organ at Risk dose. Adaptation of the IMRT plan led to a
significant improvement in PTV coverage, as well as reduced dose to the parotid glands
(upon further plan re-optimisation) and spinal cord. Whilst a benefit of ART in terms of
dose distribution to the tumour volumes, parotid glands and spinal cord has been
demonstrated in this investigation; larger prospective studies are required to establish
whether a dosimetric benefit translates into an advantage in terms of clinical outcome.
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This investigation found that 41 % of replanning events occurred at or before fraction
10; all first IMRT plan adaptations and half of the second plan adaptations had occurred
by fraction 15. This adds evidence to other publications which demonstrate that
inadequate IMRT plan dosimetry can occur early in the treatment course. An ART
strategy triggered due to notable weight loss or a loose fitting face mask would provide
adaptation much later than when dosimetrically required. The first repeat imaging and
plan assessment, to new contoured volumes, should occur early in the treatment course,
as early as fraction five or 10.
Significant resources are required to implement an ART strategy for all HNC patients.
Identifying those patients who would most benefit from ART remains challenging.
Larger scale prospective investigations would be useful to identify reliable surrogate
measures that would trigger plan adaption; hence directing resources where they are
most required. The PG-SGA score, a nutritional tool validated in the oncology setting,
should be further evaluated in this context. Streamlining the ART process may also
result in a more practical ART strategy, and should be investigated further; for example
the utilization of dose calculation on Cone Beam CT Imaging, and in particular
automated contour propagation. Ultimately, an ART strategy which improves plan
dosimetry would only be worthwhile if it results in an improvement in patient clinical
outcomes.
This investigation presents a morphologically guided approach to ART in patients with
Head and Neck Cancer. Whilst weekly imaging with high quality simulation CT and plan
optimisation (when required) resulted in a significant workload increase, it is envisaged
that the work undertaken will enable a similar approach to be taken in a more
streamlined fashion; using enhanced cone beam CT, automated contour propagation and
auto-planning tools.
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Appendix 1
Patient Generated Subjective Global Assessment (PGSGA) Worksheet
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Appendix 2
ECOG Performance Status Categories
ECOG Performance Status Scale
Grade

Descriptions

0

Normal activity. Fully active, able to carry on all pre-disease performance without
restriction.

1

Symptoms, but ambulatory. Restricted in physically strenuous activity, but
ambulatory and able to carry out work of a light or sedentary nature (e.g., light
housework, office work).

2

In bed <50% of the time. Ambulatory and capable of all self-care, but unable to
carry out any work activities. Up and about more than 50% of waking hours.

3

In bed >50% of the time. Capable of only limited self-care, confined to bed or
chair more than 50% of waking hours.

4

100% bedridden. Completely disabled. Cannot carry on any self-care. Totally
confined to bed or chair.

5

Dead.

125

Appendix 3
Concept Outline for Future Investigation
Feasibility of Cone Beam CT use for adaptive radiotherapy in Intensity
Modulated Radiotherapy (IMRT) for Head and Neck Cancer (HNC).
Background + Rationale:
IMRT for HNC is planned using a planning CT image dataset which is obtained prior to
treatment. Patient anatomy changes during radiotherapy (RT), due to weight loss and
tumour mass change. Hence the planned dose distribution is not actually delivered, with
potential for tumour underdosing and critical structure overdosing. Adaptive RT (ART)
modifies the treatment plan during RT to account for anatomical changes, for which the
“gold standard” identification method is a repeat conventional planning CT scan once
(or more) during the course of RT. However, resource implications limit its widespread
implementation. With the availability of cone beam CT (CBCT), there is potential for its
use in an ART process, allowing for a convenient and objective assessment of RT plan
quality, without the need to perform additional conventional planning CTs during the
treatment course.
Aim: To determine the feasibility of using CBCT to assess RT plan quality.
Objectives:
Primary- To measure the proportion of patients whose CBCT scans are adequate for an
assessment of RT plan quality.
Secondaryi.

To compare the time taken to contour relevant organs and evaluate the
radiotherapy plan using CBCT and conventional planning CT image sets.

ii.

To compare the dose distributions obtained using CBCT and conventional
planning CT images.

Hypotheses:
i.

The true rate of patients with adequate CBCT scans will be >95%, indicating that
further investigation into the use of CBCT in an ART protocol is worthy of
undertaking.

ii.

The process of evaluating the RT plan on CBCT images will take less time than
using conventional planning CT.
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iii.

The fan beam CT and CBCT both give the same relative difference in dose from
the original planning CT

Outcomes and measures:
Primary outcome- The assessment of RT plan quality using CBCT in a patient will be
deemed to be “inadequate” if one or more scans have one or more of the following
characteristics:
a. Image quality too poor to identify and contour the Clinical Target Volumes
(CTVs).
b. Difference in volumes of the Regions of Interest between the CBCT and
conventional planning CT to be greater than 5%.
c. The DSC comparison for the corresponding contours is less than 0.8 for parotid
glands, mandible and spinal canal; and less than 0.75 for CTV.
Secondary outcomesi.

Time (in minutes) to generate contours and perform an assessment of the RT
plan quality on the CBCT and conventional planning CT.

ii.

Measurement of the V95 for the Planning Target Volumes (PTVs); i.e. the volume
of the PTV receiving ≥95% of the prescribed dose.

iii.

Measurement of the parotid gland V26 (volume receiving ≥26Gy) and mean
dose.

iv.

Measurement of spinal cord Dmax (Maximum dose).

Study population:
Patients undergoing primary chemo-RT for mucosal HNC. Patients must be over 18
years of age and had no prior RT or surgery to the Head and Neck region.
Study design: Single arm feasibility study.
Intervention:
All patients undergo high dose CBCT whilst on treatment bed and conventional planning
CT (in CT simulation room) in the treatment position every 10 fractions during RT.
Patient weight and PG-SGA score (indicating nutritional status) will be collected weekly.
Study procedure:
A planning CT scan undertaken for treatment planning. At Fractions 1,11,21,31, a high
dose CBCT scan will be performed before treatment is delivered. Patients will have a
non-contrast conventional planning CT scan within 24 hours of the CBCT scan. Patients
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will be assessed weekly by a dietician, to record weight and PG-SGA score. Contours for
tumour volume and organs at risk will be performed by the chief investigator. The
conventional planning CT datasets will be assessed the same day for plan adequacy
(tumour coverage and critical OAR dose), with reoptimisation of the IMRT plan if
required. The CBCT datasets will be registered, contoured by the chief investigator and
assessed retrospectively.
Statistical considerations:
Sample size: 19 patients with evaluable data.
Using a 1-stage, single arm binomial design, a total of 19 participants with complete data
will provide 1-sided type 1 and type 2 error rates of 10% for distinguishing the
observed frequency of adequate CBCT from true rates of 95% (worthy of pursuit),
versus 75% (not worthy of pursuit). CBCT will be considered worthy of pursuit if 16 of
the 19 participants (84%) or more have adequate CBCT, but not if 15 of the 19 (79%) or
fewer have adequate CBCT.
Feasibility:
Two patients at a time will be recruited to the investigation, due to the resources
required.
Timeframe: Accrual of 14 patients a year, therefore 1.5 years to complete accrual.
Significance:
If CBCT scans are considered to be adequate to assess RT plan quality, their use could
result in a swifter and more practical ART process, by ensuring repeat conventional
planning CT and replanning occurs only in those patients who require IMRT plan
optimization. This would encourage more widespread adaptation of an ART protocol in
this patient population. Future investigations could look at the most practical frequency
of performing CBCT scans and the use of automated contouring software to streamline
the ART process further.
Risks:
There is additional radiation exposure to the patient of 0.2cGy per conventional
planning CT scan, leading to a total of 8cGy in total. The CBCT scan delivers 0.2 to 2cGy
per scan, with a total of 0.8 to 4cGy. This compares to the daily additional radiation
exposure of 0.02 to 0.04cGy for the current Electronic Portal Imaging method. To put
into perspective, the total delivered treatment dose for RT is 7000cGy.
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